0001493152-18-016106.txt : 20181114 0001493152-18-016106.hdr.sgml : 20181114 20181114162601 ACCESSION NUMBER: 0001493152-18-016106 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROLUNG INC CENTRAL INDEX KEY: 0001541884 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 201922768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38362 FILM NUMBER: 181184294 BUSINESS ADDRESS: STREET 1: 757 EAST SOUTH TEMPLE, SUITE 150 CITY: SALT LAKE CITY STATE: UT ZIP: 84102 BUSINESS PHONE: 801-204-9623 MAIL ADDRESS: STREET 1: 757 EAST SOUTH TEMPLE, SUITE 150 CITY: SALT LAKE CITY STATE: UT ZIP: 84102 FORMER COMPANY: FORMER CONFORMED NAME: FRESH MEDICAL LABORATORIES, INC. DATE OF NAME CHANGE: 20120209 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

[X]	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended September 30, 2018

[ ]	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from ______________ to ______________

Commission file number: 000-54600

PROLUNG, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-1922768
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

757 East South Temple, Suite 150
Salt Lake City, Utah		84102
(Address of principal executive offices)		(Zip Code)

(801) 736–0729

(Registrant’s telephone number, including area code)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[ ]	Smaller reporting company	[X]
		Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act .. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]. Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of November 14, 2018, the issuer had 3,861,848 shares of common stock, $0.001 par value, outstanding.

PROLUNG, INC.

TABLE OF CONTENTS

	Part I – Financial Information	3

Item 1	Financial Statements	3

	Condensed Consolidated Balance Sheets (Unaudited), September 30, 2018 and December 31, 2017	3

	Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months Ended September 30, 2018 and 2017	4

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2018 and 2017	5

	Notes to the Unaudited Condensed Consolidated Financial Statements	6

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3	Quantitative and Qualitative Disclosures about Market Risk	22

Item 4	Controls and Procedures	22

	Part II – Other Information	23

Item 1	Legal Proceedings	23

Item 1A	Risk Factors	23

Item 2	Unregistered Sales of Equity Securities and Use Of Proceeds	23

Item 3	Defaults Upon Senior Securities	23

Item 4	Mine Safety Disclosures	23

Item 5	Other Information	23

Item 6	Exhibits	24

Signatures		25

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ProLung, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

(Unaudited)

	September 30, 2018			December 31, 2017
Assets
Current Assets
Cash	$	720,915		$	636,639
Prepaid expenses		12,173			31,844
Deferred offering costs		-			303,401
Total Current Assets		733,088			971,884

Inventory, noncurrent		263,087			255,637
Property and equipment, net of accumulated depreciation		53,680			81,378
Intangible assets, net of accumulated amortization		149,005			156,176

Total Assets	$	1,198,860		$	1,465,075

Liabilities and Stockholders’ Deficit
Current Liabilities
Accounts payable	$	216,660		$	295,918
Accrued liabilities		228,511			25,402
Total Current Liabilities		445,171			321,320

Long-Term Liabilities
Notes payable, net of discount		3,402,860			1,206,931
Total Long-Term Liabilities		3,402,860			1,206,931

Total Liabilities		3,799,520			1,528,251

Stockholders’ Deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding		-			-
Common stock, $0.001 par value; 120,000,000 shares authorized; 3,861,848 shares issued and outstanding		3,862			3,862
Additional paid-in capital		23,148,836			21,387,907
Accumulated deficit		(25,801,869	)		(21,454,945	)
Total Stockholders’ Deficit		(2,649,171	)		(63,176	)

Total Liabilities and Stockholders’ Deficit	$	1,198,860		$	1,465,075

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

ProLung, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2018			2017			2018			2017
Revenues:
Revenue	$	-		$	-		$	-		$	-
Total revenue		-			-			-			-
Cost of revenue:		-			-			-			-
Gross margin		-			-			-			-
Operating expenses:
Research and development expense		412,951			274,407			1,524,767			1,034,934
Selling, general and administrative expense		361,876			1,067,502			2,042,167			2,472,940
Total operating expenses		774,827			1,341,909			3,566,934			3,507,874
Loss from operations		(774,827	)		(1,341,909	)		(3,566,934	)		(3,507,874	)
Other income (expense):
Write-off of deferred offering costs		-			-			(303,401	)		-
Interest expense		(216,790	)		(24,211	)		(476,589	)		(97,957	)
Net loss	$	(991,617	)	$	(1,366,120	)	$	(4,346,924	)	$	(3,605,831	)

Basic and diluted loss per share	$	(0.26	)	$	(0.35	)	$	(1.13	)	$	(1.02	)

Weighted-average common shares outstanding, basic and diluted		3,861,848			3,849,791			3,861,848			3,522,810

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

ProLung, Inc. and Subsidiary

Consolidated Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended
	September 30,
	2018			2017
Cash flows from operating activities:
Net loss	$	(4,346,924	)	$	(3,605,831	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization		29,624			24,195
(Gain) loss on sale of equipment		(3,294	)		690
Amortization of loan discount		274,758			-
Stock-based compensation		1,021,625			385,013
Write-off of deferred offering costs		303,401			-
Change in assets and liabilities:
Inventory		(7,450	)		(22,906	)
Prepaid expenses		19,671			(12,150	)
Accounts payable		(79,258	)		(163,520	)
Accrued liabilities		203,109			(32,282	)
Net cash flows from operating activities		(2,584,738	)		(3,426,791	)

Cash flows from investing activities:
Proceeds from sale of equipment		8,539			394
Payments for equipment		-			(19,842	)
Net cash flows from investing activities		8,539			(19,448	)

Cash flows from financing activities:
Proceeds from issuance of common stock and warrants		-			6,531,567
Payment for loan and stock offering costs		(322,275	)		(995,412	)
Payment on notes payable and convertible debentures		-			(285,389	)
Proceeds from notes payable		2,982,750			-
Proceeds from related party notes payable		-			35,000
Payment on related party notes payable		-			(85,000	)
Net cash flows from financing activities		2,660,475			5,200,766

Net increase in cash		84,276			1,754,527
Cash at beginning of period		636,639			28,922
Cash at end of period	$	720,915		$	1,783,449

Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	48,277		$	169,623
Supplemental disclosure of non-cash investing and financing activities:
Beneficial conversion feature	$	463,983		$	-
Warrants issued to placement agent	$	275,321		$	-
Conversion of convertible debt and interest	$	-		$	1,355,789
Conversion of related party debt and interest	$	-		$	60,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – Organization and Summary of Significant Accounting Policies

Organization

ProLung, Inc. (the “Company”), is a Delaware corporation that was incorporated on November 22, 2004 and is doing business as “ProLung.” The Company’s headquarters are located in Salt Lake City, Utah. The Company’s business is the marketing and sales of precision predictive analytical medical devices specializing in lung cancer. The Company’s principal activities are primarily developing products, seeking clearance by the U.S. Food and Drug Administration (the “FDA”) for its product, developing markets, securing strategic alliances and obtaining financing.

Principles of Consolidation

During the year ended December 31, 2012, the Company formed a wholly-owned subsidiary, Hilltop Acquisition Corporation, Inc., which has had no activity since its inception and is included in the accompanying condensed consolidated financial statements from the date of its formation.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared by management in accordance with rules and regulations promulgated by the U.S. Securities and Exchange Commission and therefore certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for them to be presented fairly, with those adjustments consisting only of normal recurring adjustments. These interim financial statements should be read in conjunction with the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K (the “Form 10-K”) for the year ended December 31, 2017. The results of operations for the three and nine months ended September 30, 2018 may not be indicative of the results to be expected for the year ending December 31, 2018.

Going Concern

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated minimal revenues thus far from its operations. The Company will not reach its planned level of operations in the United States until it receives FDA approval, if ever. The Company does have a CE mark for Europe and has licensed a portion of its technology to an entity located in China. The Company’s focus and use of funds during 2017 and the first nine months of 2018 has been on obtaining FDA approval and building an infrastructure to launch the United States market. The Company has incurred substantial and recurring losses to date from operations, continues to have a stockholders’ deficit and is currently dependent on debt and equity financing. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result relating to the recoverability and classification of the asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this risk and uncertainty.

The ability of the Company to continue as a going concern is dependent on the Company successfully obtaining additional funding, developing products that can be sold profitably, and generating cash through operating activities. Management’s plans include issuing equity or debt securities to fund capital requirements and developing ongoing operations. See Note 4 for funds raised from a convertible note offering. However, there can be no assurance the Company will raise sufficient funds and be successful in raising sufficient funds to continue as a going concern.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Basic and Diluted Loss Per Share

The Company computes basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company computes diluted loss per share by dividing net loss by the sum of the weighted-average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of diluted loss per share does not assume exercise or conversion of securities that would have an anti-dilutive effect. As of September 30, 2018, and 2017, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:

	For the Three and Nine Months Ended
	September 30,
	2018		2017
Warrants to purchase shares		1,231,559		1,205,623
Stock options		283,417		127,500
Convertible notes		698,919		201,155

Convertible Debt

The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt that has conversion features at fixed or adjustable rates that are in-the-money when issued. The BCF for the convertible instruments is recognized equal to the intrinsic value of the conversion features which is credited to additional paid-in capital.

Adoption of New Accounting Policies

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that restricted cash and cash equivalents be included as components of total cash and cash equivalents as presented on the statement of cash flows. ASU 2016-18 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and a retrospective transition method is required. The Company adopted this guidance in the first quarter of 2018 but has not historically had restricted cash resulting in no impact to previously reported periods.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), as amended. These new standards supersede all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The Company does not, at this time, expect it to have a material impact on the Company’s revenue recognition. However, the Company does expect to have significant changes to the footnote disclosures related to revenue recognition as a result of implementing these new standards. As the Company has elected to be treated as an emerging growth company, this standard will be implemented effective January 1, 2019.

In February 2016, the FASB issued ASU No. 2016-02: Leases. ASU 2016-02 requires companies to generally recognize on the balance sheet, operating and financing lease liabilities and corresponding right-of-use assets. ASU 2016-02 will be effective for the Company’s fiscal year beginning January 1, 2020 on a modified retrospective basis and earlier adoption is permitted. Management is currently evaluating the impact of the pending adoption of ASU 2016-02 and based on the Company’s one lease agreement, does not anticipate a material impact to the condensed consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II). Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within current account guidance with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted. The Company has not had any instruments that meet the criteria for Part I, but could issue such instruments in the future; therefore, the Company is currently evaluating the impact that the adoption of the standard could have on its future condensed consolidated financial statements.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities was issued in August 2017. The amendments under ASU 2017-12, refine and expand hedge accounting requirements for both financial (e.g., interest rate) and commodity risks. Its provisions create more transparency around how economic results are presented, both on the face of the financial statements and in the footnotes. It also makes certain targeted improvements to simplify the application of hedge accounting guidance. The standard is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company will adopt this ASU on January 1, 2020. The Company does not currently have any derivative or hedging instruments but may in the future.

In June 2018, the FASB issued ASU 2018-07 Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018; Early adoption is permitted, but no earlier than the Company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company does not currently have any stock options to non-employees that have a vesting requirement. However, if the Company were to issue options to a non-employee with a vesting provision the implementation of this standard would provide a consistent expense over the service period of the non-employee.

In August 2018, the FASB issued ASU 2018-13, Changes to Disclosure Requirements for Fair Value Measurements, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact that the adoption of the standard could have on its future condensed consolidated financial statements.

Note 2 – Inventory

Inventory principally consists of the cost of materials purchased and assembled. The cost of inventory also includes the costs of direct labor for the assembly and certain indirect costs incurred in connection with purchasing of parts and the assembly of products. Inventory consists of the following at September 30, 2018 and December 31, 2017:

	September 30, 2018		December 31, 2017

Raw materials	$	73,415	$	66,417
Work in progress		13,340		12,465
Finished goods		176,332		176,755

Total inventory		263,087		255,637
Less: carrying value of inventory not deemed to be a current asset		263,087		255,637

Inventory, included in current assets	$	-	$	-

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 3 – Accrued Liabilities

Accrued liabilities consisted of the following at September 30, 2018 and December 31, 2017:

	September 30, 2018		December 31, 2017

Accrued interest	$	151,770	$	-
Accrued royalties		17,873		17,873
Accrued payroll and payroll taxes		58,868		7,529

Total Accrued Liabilities	$	228,511	$	25,402

Note 4 –Notes Payable

2018 Transactions

In March 2018, the Company began issuing 8% convertible promissory notes (“convertible notes”). The convertible notes are unsecured. Principal and accrued interest are due two years from the date of issuance. The holder of the convertible note is entitled, at its option, to convert all, or any portion of the outstanding principal and interest, into shares of the Company’s common stock at a conversion price of $6.30 per share. Interest accruing from the date of issuance to the conversion date shall be paid on the maturity date. If the Company completes a public offering of its common stock, the convertible promissory notes and accrued interest automatically convert into common stock at the lower of i) 90% of the public offering price or ii) $6.30 per share.

During the nine months ended September 30, 2018, the Company issued $2,982,750 in convertible promissory notes and accrued interest totaling $127,631 which would be convertible into 493,740 shares of common stock (473,467 shares for principal and 20,273 shares for interest).

On the date the convertible notes were issued, the fair value of the Company’s stock was estimated to be $7.28 per share which was greater than the conversion rate of $6.30. The $0.98 per share difference is considered a beneficial conversion feature. The beneficial conversion feature related to the convertible notes was $463,983. On the date of issuance, the Company also assessed the conversion feature for possible derivative treatment (under ASC 815) and determined the conversion feature was indexed to the Company’s common stock and thus not a derivative.

The Company utilized a placement agent in connection with the offering which entitled them to a cash commission of 10% of the convertible notes issued, $25,000 for non-accountable expenses and warrants to purchase 10% of the potential conversion shares of stock associated with the principal portion of convertible notes issued by the Company (47,186 warrants). Pursuant to this agreement, the Company incurred cash commission fees to the placement agent of $322,275. The value of the 47,186 warrants was $275,321 ($5.83 per warrant), derived utilizing the Black-Scholes Pricing Model with the following weighted average assumptions:

Expected life	2.5 years
Exercise price	$	7.29
Expected volatility		160	%
Expected dividends		n/a
Risk-free interest rate		2.35	%

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The $597,596 in loan costs incurred was added to the $463,983 beneficial conversion feature creating a debt discount (“discount”) of $1,061,579. The accompanying condensed consolidated balance sheet reflects the convertible notes net of the discount. The discount will be amortized as a component of interest expense over the term of the convertible notes. During the three and nine months ended September 30, 2018, the Company recognized interest expense of $133,977 and $274,758 related to the amortization of the beneficial conversion feature and loan costs. As of September 30, 2018, the unamortized balance of the beneficial conversion feature and loan costs is $786,821.

2017 Transactions

During the nine months ended September 30, 2017 convertible debentures were converted or repaid as follows: The Company repaid $164,000 in principal along with $25,700 in related accrued interest. The remaining convertible debenture holders elected to convert $1,093,050 in principal along with $162,739 in related interest into 241,500 shares of common stock at a rate of $5.20 per share.

During the nine months ended September 30, 2017, $89,389 of principal of a master note to an individual related to an executive officer of the Company was repaid along with interest of $39,071. In addition, the noteholder elected to convert the remaining $100,000 of principal for 8,334 shares of common stock as well as 8,334 warrants to purchase stock at a price of $12.00 per unit.

During the nine months ended September 30, 2017, $105,000 of related-party notes were repaid along with interest and fees of $5,000. The Company repaid $50,000 in cash, and the individual elected to convert the remaining $60,000 into 5,000 shares of common stock, and 5,000 warrants to purchase stock, at a price of $12 per share. During the nine months ended September 30, 2017, the same individual made a short-term advance of $35,000 that did not bear interest which was repaid during the nine months ended September 30, 2017.

During the nine months ended September 30, 2017, $32,000 of principal along with $1,185 of related accrued interest for a third-party note was repaid with cash.

Notes payable are summarized as follows:

	September 30, 2018		December 31, 2017
Convertible notes payable net of $786,821 in discount and loan costs; unsecured; interest at 8.00%; due March through May 2020	$	2,195,929	$	-

Convertible notes payable; unsecured; interest at 8.00%; due November 2020		1,206,931		1,206,931

Notes payable	$	3,402,860	$	1,206,931

Note 5 – Common Stock

Public Offering of Common Stock of the Company

During 2017 through February 2018, the Company filed a Registration Statement and subsequent amendments on Form S-1 (the “Registration Statement”). The Registration Statement related to a potential public offering of the Company’s common stock. There was no assurance that any shares would be offered and sold pursuant to such Registration Statement. Through February 2018, the Company incurred cash offering costs totaling $303,401 which were to be offset against the proceeds received if such offering was completed. In February 2018, the Board suspended the offering, and in June 2018, the Board decided not to pursue the public offering in the near future and the Company wrote-off the deferred offering costs to expense.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Private Placement of Common Stock of the Company

During 2016 and through May 2017, the Company issued equity under a private placement agreement. The Company engaged two separate placement agents during different time periods in connection with the offering, which placement agents were entitled to a cash commission of ten percent of the issuance price of the common stock sold in the offering, and one share of common stock of the Company for each ten shares of the Company’s common stock sold in the offering. Pursuant to these agreements, the Company had incurred commission fees to the placement agents of $826,146 together with 67,326 shares of common stock as of September 30, 2017. For the nine months ended September 30, 2017, the Company received subscriptions for $6,531,567 and paid $664,452 of cash offering costs. As of September 30, 2017, the total adjusted maximum offering amount of $8.2 million was subscribed for and the offering was closed.

Common Stock Issued for Conversion of Convertible Notes and Debentures

During the nine months ended September 30, 2017 the following conversions occurred:

	●	$1,093,050 of convertible debentures and $162,739 of accrued interest was converted at $5.20 per share into 241,500 shares of common stock;

	●	As partial settlement of a note payable to a relative of an Executive Officer, $100,000 was converted at $12.00 per share into 8,334 shares of common stock;

	●	As partial settlement of a related party note, $55,000 of principal and $5,000 of interest was converted at $12.00 per share into 5,000 shares of common stock.

Common Stock Issued for Services

During the nine months ended September 30, 2017, the Company issued 6,250 shares of common stock with a total value of $53,500 to certain Board members and consultants for services rendered.

Total stock-based compensation expense from all sources for the three and nine months ended September 30, 2018 and 2017, including stock-based compensation for the options and warrants discussed in Note 6 and Note 7, has been included in the condensed consolidated statements of operations as follows:

	For the Three Months Ended					For the Nine Months Ended
	September 30,					September 30,
	2018			2017		2018		2017

Research and development expense	$	99,129		$	-	$	579,754	$	-
Selling, general and administrative expense		(67,139	)		261,153		441,871		385,013

Total share-based compensation	$	31,990		$	261,153	$	1,021,625	$	385,013

Note 6 – Common Stock Options

Equity Incentive Plan

In July 2017, the shareholders approved the ProLung, Inc. Stock Incentive Plan (the “Plan”). The Plan authorizes the Board’s Compensation Committee to grant incentive stock options, non-incentive stock options, stock bonuses, restricted stock, and performance-based awards to directors, officers and employees and non-employee agents, consultants, advisers and independent contractors of the Company or any parent or subsidiary of the Company.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The total number of initial shares of Common Stock authorized for issuance under the Plan is 500,000 shares. The authorized shares will automatically increase on January 1 of each year, for ten consecutive years, commencing on January 1, 2018, by the lesser of (i) 40,000 shares of Common Stock (i.e., 8% of the shares originally authorized to be issued), or (ii) such number of shares of common stock (if any) the Board may earlier designate in writing. If the automatic increases are not limited by the Board, there will be 900,000 shares of common stock authorized under the Plan in January 1, 2027.

Board and Key Employee Option Grants

In March 2018, the Board’s compensation committee approved the issuance of 938 options to a new director of the Company at an exercise price of $8 per option. One third of the options vest immediately with the remaining two thirds vesting at June 30, 2018. The fair value of these options was $6.18 per option or $5,794 and will be expensed over the relative vesting period.

In May 2018, as part of a bonus agreement the Board approved the issuance of 30,000 options to our Chief Medical Officer with an exercise price of $8 per option. These options vested upon issuance. The fair value of these options was $6.28 per option or $188,289 and was expensed upon issuance.

At a Board meeting in May 2018, the Board approved the issuance of stock options as payment for their 2018 Board fees in lieu of cash which included the first quarter accrual of $105,500. The Company issued 50,016 options to these Board members with one third vesting immediately, one third vesting on June 30, 2018 and the remaining one third vesting on September 30, 2018. The fair value of these options was $6.07 per option or $303,696, were expensed over the relative vesting period and are fully vested at September 30, 2018

During the nine months ended September 30, 2018, certain employees separated from the Company and several directors resigned resulting in 48,893 options being forfeited and $140,303 of future expense being eliminated.

The fair value was computed using the Black Scholes method using the following weighted-average assumptions:

Expected life	5.06 Years
Exercise price	$	8.00
Expected volatility		125	%
Expected dividends		None
Risk-free interest rate		2.81	%

The Company recorded an expense of $227,262 and $1,049,054 for the three and nine months ended September 30, 2018, respectively, related to the amortization of options issued under the Plan. The remaining unrecognized expense of $162,488 will be recognized through September 30, 2019 with a weighted average term of 1.0 years.

CEO Stock Option Incentive

The Company granted the Company’s former CEO stock option incentives related to FDA approval. The stock option shall expire 10 years after the grant date and shall vest with respect to a number of options of Common Stock upon the receipt of FDA marketing authorization (as defined below), with such number of options to be as follows:

	●	112,500 options if FDA marketing authorization is obtained after January 1, 2018 and on or before July 1, 2018;

	●	75,000 options if FDA marketing authorization is obtained after July 1, 2018 and on or before January 1, 2019;

	●	37,500 options if FDA marketing authorization is obtained after January 1, 2019 and on or before January 1, 2020.

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The Company considered these options to be performance based with August 9, 2017 the grant date. Solely for accounting purposes, the Company originally estimated the conditions for vesting will be met between July and December 2018. Based on this estimate, management believed the most probable number of options to be issued would be 75,000, less a pro-rata reduction due to the CEO’s separation from the Company.

During the three months ended September 30, 2018, the Company concluded it was improbable that FDA marketing authorization would be obtained by December 31, 2018. The Company updated their estimate whereby the conditions for vesting will likely be met by December 31, 2019. Based on the December 31, 2019 estimate, the number of options decreased from 75,000 to 37,500 (less a pro-rata reduction due the CEO’s separation from the Company) and the resulting value from $472,000 to $223,000; as the service period was extended from December 31, 2018 to December 31, 2019. Through the date of the change in estimate, the Company had amortized $301,375 of compensation expense related to the original estimate. Based on the updated estimate the Company should have amortized $106,103 of compensation expense. As a result, the Company recognized a net reversal of compensation expense of $195,272 and $27,429 for the three and nine months ended September 30, 2018, respectively. The remaining $116,281 is being recognized through December 31, 2019, less a pro-rata reduction due to the CEO’s separation from the Company.

As of September 30, 2018, there are currently 178,293 options available for issuance under the Plan.

A summary of option activity for the nine months ended September 30, 2018 is presented below:

						Weighted		Aggregate
				Weighted		Average		Intrinsic
	Shares			Average		Remaining		Value of
	Under			Exercise		Contractual		Vested
	Options			Price		Life		Options
Outstanding at December 31, 2017		331,000		$	8.05		10.0 years	$	-
Issued		80,954		$	8.00
Adjustment		(37,500	)	$	8.00
Forfeited/Expired		(91,037	)	$	8.00
Outstanding at September 30, 2018		283,417		$	8.00		9.28 years	$	-
Vested at September 30, 2018		195,198		$	8.00		9.22 years	$	-

ProLung, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 7 – Common Stock Warrants

A summary of warrant activity for the nine months ended September 30, 2018 is presented below:

						Weighted		Aggregate
				Weighted		Average		Intrinsic
	Shares			Average		Remaining		Value of
	Under			Exercise		Contractual		Vested
	Warrants			Price		Life		Warrants
Outstanding at December 31, 2017		1,184,998		$	9.16		1.9 years	$	1,160,404
Issued		47,186		$	7.29
Exercised		-
Expired/Forfeited		(625	)	$	0.01
Outstanding at September 30, 2018		1,231,559		$	9.02		1.1 years	$	1,155,860

The intrinsic value at September 30, 2018 is calculated at $7.28 per share less the exercise price, based on management’s latest estimate of the fair value of the shares of common stock, which is the latest price the Company has issued shares of common stock for cash.

The Company recognized $35,446 and $70,360 as share-based compensation related to the vesting of warrant shares for the three and nine months ended September 30, 2017, respectively.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q (this “Report”) and the Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Form 10-K”) of ProLung, Inc. (the “Company”).

The statements contained in this Report that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should” and “would,” as well as similar expressions, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward looking. The forward-looking statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties, or assumptions, many of which are beyond our control that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause these differences include the following:

	●	we are a development stage company with limited revenue and no assurance of earning significant revenue over the long term;

	●	our future success may be dependent upon additional financings to fund our operations, particularly if we obtain approval from the U.S. Food and Drug Administration (the “FDA”) to market our non-invasive lung cancer risk stratification test (the “ProLung Test”), if we fail to obtain such capital, which may become more difficult if we do not receive FDA approval, we may be unable to continue as a going concern;

	●	our clinical studies may produce unfavorable results which could prevent or delay us from obtaining FDA and other regulatory approvals;

	●	we must obtain regulatory approval in the US and other non-European Union markets to be able to commence marketing and sales in those markets;

	●	if we obtain FDA approval, we will be subject to Medical Device Reporting, or MDR, requirements, which may lead to inquiries, injunctions or liabilities;

	●	we offer and sell a single testing product;

	●	we may eventually want to expand the ProLung Test to other cancer targets. ProLung does not have clinical data suggesting that the ProLung Test is effective in other cancers and the ProLung Test may not be effective in other cancers;

	●	we are a small company and may be unable to compete with competitive technologies;

	●	we may be unable to protect our intellectual property rights, which are important to the potential value of our products and company;

	●	we may incur significant costs and liability if we infringe, or are accused of infringing on, the intellectual property rights of others;

	●	although we are capable of internally manufacturing to meet foreseeable demand, we may at some time be dependent upon contract manufacturers to safely and timely manufacture our products;

	●	there is no guarantee that FDA approval will lead to the ProLung Test being approved by payors for reimbursement;

	●	our ProLung Test may produce false positive and false negative results; and

	●	other factors discussed in our 2017 Form 10-K.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Overview

In this Report, ProLung, Inc. and its consolidated subsidiary are referred to as “ProLung” in addition to as the “Company” versions of “we” or “us.” We have registered trademarks under ProLungdx®, Fresh Medical Laboratories®, ProLung®, EPN Scan®, Electro Pulmonary Nodule Scanner® and EPN Scanner®. Any other trademarks and service marks used in this Report are the property of their respective holders.

We are a medical device company that is developing, testing and commercializing its non-invasive lung cancer risk stratification test or ProLung Test. The ProLung Test was developed to be adjunctive to Computed Tomography (“CT”), or what is commonly referred to as a “CT scan” of the chest. The ProLung Test is designed to assist in evaluating the risk associated with a CT finding in the lung that is suspicious for cancer.

ProLung’s bioconductance technology is a “mass averaging” bioconductance device that has shown utility in studies to evaluate the risk of lung cancer in patients with lesions of the lung in well-controlled clinical trials. The novel “mass averaging” bioconductance technology of the Company refers to the simultaneous consideration of multiple measurement pathways.

Subject to FDA approval, the ProLung Test will be introduced to the market like a standard predictive analytic test without the need for transmission of a physical sample or specimen. Instead, the ProLung Test acquires precision bioconductance measurements by means of a patented probe and disposable diaphoretic electrodes placed on the back and arms. The data containing precision measurements is processed by a proprietary classified algorithm, and a report is electronically generated that may be used by the physician, in addition to other risk factors such as nodule size, family history, gender, histology and other risk stratification information, to evaluate patients with suspicious masses or lesions identified by the CT scan. The ProLung Test is immediate, pain-free, non-invasive, and non-radiating. It requires little patient preparation and can be completed in less than 30 minutes by a proficient technician.

When patients at high risk of lung cancer have suspicious lung findings after CT evaluation, clarifying the risk of the disease, or risk stratification, has the potential to reduce the cost, anxiety, and/or time associated with the inaccurate and/or delayed diagnosis of lung cancer. Risk stratification may also play a role in identifying those patients who need to modulate the extent and frequency of follow-up. On December 31, 2013, the U.S. Preventative Services Task Force recommended CT screening guidelines for lung cancer in adults aged 55 to 80 who have a 30 pack-year history and currently smoke or have quit smoking in the past 15 years. On February 5, 2016, Medicare began to pay for lung cancer screening. The guideline and its related reimbursement by Medicare are expected to increase the number of individuals identified with suspicious findings in the lung that may be candidates for the ProLung Test. The reimbursement also expected to increase the development of lung cancer centers for interdisciplinary review of screening results. We believe that these changes may increase the number of patients seeking further risk assessment from the administrations of tests like the ProLung Test.

On May 10, 2013, the ProLung Test received the “CE” mark in Europe for its Electro Pulmonary Nodule Scanner. This marking is regulatory approval that clears the marketing and sales of the ProLung Test in the European Economic Area and European Free Trade Association Countries representing 509 million individuals and 31-member states. The new screening guidelines and Medicare coverage announced in the U.S. for lung cancer screening are not available in Europe.

In the United States, ProLung applied for marketing approval under Section 510(k) from the FDA. In February 2015, we received a letter from the FDA identifying a number of issues, questions, and concerns in our application, including the risk classification of the test, the study design and study analysis along with what we consider other less important questions. In subsequent meetings with the FDA, ProLung succeeded in reducing the number of concerns and was asked to complete an additional study. We must complete the requested clinical research and resubmit the application with the results of the requested study and resolve or negotiate the removal of the remaining issues previously identified by the FDA as well as address possible issues to be identified in the future. Unless and until we obtain FDA approval, we are not permitted to market or sell our ProLung Test in the United States.

From inception to date, we have generated limited revenues. During the year ended December 31, 2014, we commenced selling the ProLung Test to customers in the European Union but generated no revenue in the European Union in the periods covered by this Report.

We plan to continue the development and deployment of medical devices and procedures specializing in the immediate, non-invasive evaluation of indeterminate masses in the lung seen in CT and radiography. We anticipate the need to fund expansion and market growth by raising capital over the next two years. The amount of capital needed could change based on the opportunities available to us and the ability to expand our markets.

We are an “emerging growth company” and a “smaller reporting company” under the federal securities laws and are subject to reduced public company reporting requirements.

Results of Operations

The following discussion is included to describe our consolidated financial position and results of operations. The condensed consolidated financial statements and notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Three Months Ended September 30, 2018 compared to the Three Months Ended September 30, 2017

Revenues and Cost of Revenue. During the three months ended September 30, 2018 and 2017 we had no revenues or cost of revenues.

Operating Expenses. Total operating expenses for the three months ended September 30, 2018 were $774,827 compared to the total operating expenses for the three months ended September 30, 2017 of $1,341,909, representing a decrease of $567,082. Operating expenses have been classified by management as either research and development or selling, general and administrative based on an assignment of certain expenses directly to these classifications or based on management’s allocation of certain expenses between these classifications.

During the first half of 2017, we concluded our private placement which provided additional capital which enabled us to access various professionals and consultants for a future public offering, business development and administrative costs. In anticipation of marketing our product and completing a public offering, we hired additional personnel increasing our payroll costs. During the three months ended September 30, 2018, our focus has been eliminating costs and gaining FDA approval. In July 2017, our Board authorized the ProLung, Inc. Stock Incentive Plan; whereby, we issued the Board, our former CEO and significant employees options which resulted in the amortization of the value of the options during the second half of 2017 and throughout 2018. In September 2018 certain estimates regarding our former CEO’s options were modified, resulting in a reversal of some compensation expense. The above issues resulted in a decrease year over year in operating costs during the three months ended September 30, 2018. A further discussion as to the changes in research and development expense and selling, general and administrative expense is more fully discussed below.

Research and Development Expense. Research and development expense for the three months ended September 30, 2018, was $412,951 compared to research and development expense of $274,407 for the three months ended September 30, 2017; representing an increase of $138,544. This increase was due to our focus during the three months ended September 31, 2018 on obtaining FDA approval for the ProLung Test. We also recorded $99,128 of stock-based compensation during 2018 to our employees classified as research and development employees in full or in part. We did not have this expense during the same period in 2017.

Selling, General and Administrative Expense. Selling, general and administrative expense for the three months ended September 30, 2018 was $361,876 compared to selling, general and administrative expense of $1,067,502 for the three months ended September 30, 2017; representing a decrease of $705,626. During the three months ended September 30, 2017, we commenced an offering of our common stock whereby we incurred significant up-front travel, legal, professional and consulting expense during the three months ended September 30, 2017. These costs primarily related to advisory fees, investor relations and brand awareness as we commenced the offering process and were not included as part of deferred offering costs. In February 2018, we elected to terminate our relationship with our underwriter and postponed the offering. As a result, we did not incur these costs during the three months ended September 30, 2018. Also, during the three months ended September 30, 2018 we updated our estimate of when our former CEO would vest in his stock options. As a result, we reversed previously recognized expense of $195,272 related to these options.

Interest Expense. Interest expense for the three months ended September 30, 2018 was $216,790 as compared to $24,211 for the three months ended September 30, 2017 representing an increase of $192,579. From March to May 2018, we issued approximately $3 million in 8% convertible promissory notes. The convertible notes were issued with a beneficial conversion feature and cash and equity loan costs. Under these new notes, we incurred both interest expense and the amortization of discount which we did not have during the three months ended September 30, 2017. These convertible notes mature two years from the date of issuance and we anticipate our interest expense will be consistent with the current quarter amount during the term of these notes. However, if the convertible note is converted, any unamortized discount will be immediately charged against interest.

Nine Months Ended September 30, 2018 compared to the Nine Months Ended September 30, 2017

Revenues and Cost of Revenue. During the nine months ended September 30, 2018 and 2017 we had no revenues or cost of revenues.

Operating Expenses. Total operating expenses for the nine months ended September 30, 2018 were $3,566,934 compared to the total operating expenses for the nine months ended September 30, 2017 of $3,507,874 representing an increase of $59,060 Operating expenses have been classified by management as either research and development or selling, general and administrative based on an assignment of certain expenses directly to these classifications or based on management’s allocation of certain expenses between these classifications.

The overall increase in operating expenses during the nine months ended September 30, 2018, is primarily a result of stock-based compensation related to options issued under our Stock Incentive Plan and our current focus of gaining FDA approval for the ProLung Test. A further discussion as to the changes in research and development expense and selling, general and administrative expense are more fully discussed below.

Research and Development Expense. Research and development expense for the nine months ended September 30, 2018, was $1,524,767 compared to research and development expense of $1,034,934 for the nine months ended September 30, 2017; representing an increase of $489,833. This increase during 2018 was due to our focus on obtaining FDA approval for the ProLung Test. During the period we entered into an agreement with our Chief Medical Officer resulting in a total additional expense of $308,307, which includes $188,307 of stock-based compensation. We also recorded $391,446 of stock-based compensation during 2018 to our employees classified as research and development employees in full or in part. We did not have this expense during the same period in 2017. This was primarily offset by less travel and clinical costs during 2018, due to our on-site clinical trials winding down.

Selling, General and Administrative Expense. Selling, general and administrative expense for the nine months ended September 30, 2018, was $2,042,167 compared to selling, general and administrative expense of $2,472,940 for the nine months ended September 30, 2017; representing a decrease of $430,773. During the nine months ended September 30, 2017, we commenced an offering of our common stock whereby we incurred significant up-front, legal, professional and consulting expense and travel through the nine months ended September 30, 2017. These costs primarily related to advisory fees, investor relations and brand awareness as we commenced the offering process and were not included as part of deferred offering costs. In February 2018, we elected to terminate our relationship with our underwriter and postponed indefinitely the offering. As a result, we did not incur these costs from March 2018 through September 30, 2018. Also, during the nine months ended September 30, 2018 we updated our estimate of when our former CEO would vest in his stock options. As a result, we reversed previously recognized expense of $195,272 related to these options.

Other Expense. Other expense for the nine months ended September 30, 2018 was $779,990 as compared to $97,957 for the nine months ended September 30, 2017 representing an increase of $682,033. The increase costs consist of the following:

Interest Expense – From March through May 2018, we issued approximately $3 million in 8% convertible promissory notes. The convertible notes were issued with a beneficial conversion feature and cash and equity loan costs. Under these new notes, we incurred both interest and the amortization of discount which we did not have during the nine months ended September 30, 2017. These convertible notes mature two years from the date of issuance, and we anticipate our interest expense will be consistent with the current period amount during the term of these notes. However, if the convertible notes are converted, any unamortized discount will be immediately charged against interest.

Write-Off of Deferred Offering Costs – During 2017 and 2018, the Company filed a Registration Statement and numerous amendments related to a potential public offering of the Company’s common stock. There was no assurance that any shares would be offered and sold pursuant to such Registration Statement. Through February 2018, the Company incurred cash offering costs totaling $303,401 which were to be offset against the proceeds received if such offering was completed. In February 2018, the Board suspended the offering, and in June 2018, the Board decided not to pursue the public offering in the near future and the Company wrote-off the deferred offering costs to expense.

Liquidity and Capital Resources

The following is a summary of our key liquidity measures at September 30, 2018 and 2017:

	September 30, 2018			December 31, 2017

Cash	$	720,915		$	636,639

Current assets		733,088			971,884
Current liabilities		(396,660	)		(321,320	)

Working capital	$	336,428		$	650,564

We need additional capital to continue our operations. During the nine months ended September 30, 2018 we issued $2,667,750 in convertible notes, net of loan fees paid. If we obtain FDA clearance to market the ProLung Test we expect that our need for capital will expand. We expect that in order to raise such capital we may be required to issue equity securities, debt securities and rights to acquire equity securities. We have no existing commitment to provide capital, and given our early stage of development, we may be unable to raise sufficient capital when needed and, in any case, will likely be required to pay a high price for capital.

Our future capital requirements and adequacy of available funds will depend on many factors including:

	●	our ability to obtain regulatory approval for the marketing of the ProLung Test in markets outside of Europe, including in the US;

	●	our ability to successfully commercialize our ProLung Test, ProLung System, and related products and the market acceptance of these products;

	●	reimbursement for our ProLung Test by Medicaid, Medicare and private third-party payors;

	●	the timing of our orders, if any, and the pricing and payment terms of those orders;

	●	our ability to establish and maintain collaborative arrangements with distributors for the development and commercialization of certain product opportunities;

	●	the cost of manufacturing and production scale-up;

	●	our financial results;

	●	the cost and availability of capital generally; and

	●	the occurrence of unexpected adverse expenses or events.

Notes Payable

In March 2018, we began issuing 8% convertible promissory notes (“convertible notes”). The convertible notes are unsecured. Principal and accrued interest are due two years from the date of issuance. The holder of the convertible note is entitled, at its option, to convert all, or any portion of the outstanding principal and interest, into shares of our common stock at a conversion price of $6.30 per share. Interest accruing from the date of issuance to the conversion date shall be paid on the maturity date. If the Company completes a public offering of its common stock, the convertible promissory notes and accrued interest automatically convert into common stock at the lower of i) 90% of the public offering price or ii) $6.30 per share. Through September 30, 2018, we have issued $2,982,750 in convertible promissory notes and paid fees of $322,275 related to these notes.

Cash provided by (used in) operating, investing and financing activities

Cash provided by (used in) operating, investing and financing activities for the nine months ended September 30, 2018 and 2017 is as follows:

Operating Activities

	Nine Months Ended September 30,
	2018			2017

Operating activities	$	(2,584,738	)	$	(3,426,791	)
Investing activities		8,539			(19,448	)
Financing activities		2,660,475			5,200,766

Net increase in cash	$	84,276		$	1,754,527

For the nine months ended September 30, 2018, the differences between our net loss and net cash used in operating activities were due to net non-cash charges totaling $1,626,114 for stock-based compensation, amortization of debt discount, depreciation and the write-off of deferred offering costs.

For the nine months ended September 30, 2017, the differences between our net loss and net cash used in operating activities were due to net non-cash charges totaling $409,898 for stock-based compensation and depreciation.

Investing Activities

During the nine months ended September 30, 2018 and 2017, the Company had only insignificant investing activities which were related to the buying or selling of equipment.

Financing Activities

During the nine months ended September 30, 2018, cash flows from financing activities totaled $2,660,475. The cash flows were related to proceeds received from the issuance of convertible notes, net of loan costs paid.

During the nine months ended September 30, 2017, cash flows from financing activities totaled $5,200,766. These cash flows were related to gross proceeds of $6,531,567 received from our private placement of common shares and warrants to acquire common shares. Such private placement concluded in the quarter ended September 30, 2017. This was partially offset by direct and deferred offering costs of $995,412. During the nine months ended September 30, 2017, we made debenture payments, third party loan payments and related party payments of $164,000, $121,389 and $50,000, respectively. During the nine months ended September 30, 2017, a related party advanced the Company $35,000 which was repaid during the same period.

Critical Accounting Policies and Estimates

The accompanying discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. We evaluate our estimates on an on-going basis. We base our estimates on historical experience and on other assumptions that are believed to be reasonable under the circumstances. However, future events may cause us to change our assumptions and estimates, which may require adjustment. Actual results could differ from these estimates. We have determined that for the periods reported in this Report on Form 10-Q the following accounting policies and estimates are critical in understanding our financial condition and results of operations.

Inventory – Inventory is valued at the lower of cost or market value, with cost determined based on the first-in-first-out method. Management evaluates inventory for obsolescence based on expectations about future demand and marketability of products, and if necessary, reduces inventory to the lower of cost or market through the use of an inventory valuation account for obsolescence. The estimated cost of inventory not expected to be converted to cash within one year is reflected as “Inventory, noncurrent” in the condensed consolidated balance sheet.

Long-lived Assets – Long-lived assets, including property and equipment, and intangible assets are tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. When such events occur, we compare the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset or asset group to the carrying amount of the long-lived asset or asset group. If this comparison indicates that there is an impairment, the amount of the impairment is calculated based on fair value.

Convertible Debt – The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt that has conversion features at fixed or adjustable rates that are in-the-money when issued. The BCF for the convertible instruments is recognized as a discount equal to the intrinsic value of the conversion features, which is also recorded as an increase to additional paid-in capital.

Stock-based Compensation – The Company measures the cost of employee and consulting services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The awards issued are valued using a fair value-based measurement method. The resulting cost is recognized over the period during which an employee or consultant is required to provide services in exchange for the award, usually the vesting period.

Emerging Growth Company – We are an “emerging growth company” under the federal securities laws and will be subject to reduced public company reporting requirements. In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Although we have not delayed the adoption of any accounting standards, we may choose to take advantage of the extended transition period for complying with new or revised accounting standards in the future.

Off Balance Sheet Arrangements

The Company has not had any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This item is not applicable to the Company because the Company is a smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of September 30, 2018. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Based on that evaluation, our chief executive officer and chief financial officer concluded as of September 30, 2018 that our disclosure controls and procedures are designed at a reasonable assurance level and were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure as a result the following material weakness in our internal controls and procedures existed:

The Company did not maintain effective entity-level internal controls as defined by the framework issued by COSO. Specifically, the Company did not effectively segregate certain accounting duties due to the small size of the Company’s accounting staff. In addition, there were lapses in the Company’s expense documentation and related controls.

In order to mitigate these material weaknesses the audit committee holds regular meetings whereby we determine whether a new control can be implemented to mitigate these risks at a reasonable cost, it is implemented as soon as possible.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting that occurred in the nine months ended September 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On July 31, 2018, the Company filed a complaint (the “Complaint”) in the District of Utah, Central Division (Case No. 2:18-cv-00613-EJF), against Steven C. Eror, former CEO and director, Todd Morgan, former Chairman of the Board, Michael Christensen, Weild & Co, LLC, United Shareholders of ProLung and John Does 1-250. The Complaint alleges that the defendants have been engaged in an unlawful proxy solicitation in violation of Section 14(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) by misleading statements and omissions, failed to report the formation of a group and its intent in violation of Section 13(d) under the Exchange Act, failed to file a report on Form 3 under Section 16 of the Exchange Act, infringed the trademarks of the Company and engaged in unfair competition. The Complaint seeks declaratory relief, injunctive relief, damages and attorneys’ fees. On September 14, 2018, we filed an amended complaint to name additional defendants. The defendants have not filed an answer or response to the Amended Complaint, and have not filed counterclaims.

Except as set forth above, we know of no existing or pending material legal proceedings to which the Company is a party nor of any proceedings in which any of our directors, officers or any of their respective affiliates, or any beneficial stockholder is an adverse party or has a material interest adverse to our interest.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and, as a result, are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

3.1		Third Amended and Restated Certificate of Incorporation, as amended by Certificate of Amendment dated October 10, 2017⁽¹⁾

3.2		Amended and Restated By-Laws⁽¹⁾

31.1		Certification Pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as Amended*

32.1		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101 INS		XBRL Instance Document*

101 SCH		XBRL Schema Document*

101 CAL		XBRL Calculation Linkbase Document*

101 LAB		XBRL Labels Linkbase Document*

101 PRE		XBRL Presentation Linkbase Document*

101 DEF		XBRL Definition Linkbase Document*

(1)

Incorporated by reference from our Current Report on Form 8-K filed with the SEC on July 19, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PROLUNG, Inc.

November 14, 2018	By:	/s/ Jared Bauer
Date		Jared Bauer
		Interim Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jared Bauer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of ProLung, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:

November 14, 2018

/s/ Jared Bauer

Interim Chief Executive Officer

(Principal Executive and Financial Officer)

EX-32.1 3 ex32-1.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ProLung, Inc. (the “Company”) for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission (the “Report”), I, Jared Bauer, Interim Chief Executive and Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	2.	The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:

November 14, 2018

/s/ Jared Bauer

Jared Bauer

Interim Chief Executive Officer

(Principal Executive Officer)

EX-101.INS 4 lung-20180930.xml XBRL INSTANCE FILE 0001541884 2018-01-01 2018-09-30 0001541884 2017-12-31 0001541884 2016-12-31 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001541884 LUNG:WarrantsMember 2017-12-31 0001541884 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001541884 LUNG:ConvertibleNotesMember 2018-01-01 2018-09-30 0001541884 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001541884 LUNG:ConvertibleNotesMember 2017-01-01 2017-09-30 0001541884 LUNG:BoardAndKeyEmployeeOptionGrantsMember 2018-01-01 2018-09-30 0001541884 LUNG:StockIncentivePlanMember 2017-07-31 0001541884 LUNG:StockIncentivePlanMember 2017-07-02 2017-07-31 0001541884 LUNG:USFoodAndDrugAdministrationMember 2018-01-01 2018-09-30 0001541884 LUNG:USFoodAndDrugAdministrationMember LUNG:OnOrBeforeJulyOneTwoThousandAndEighteenMember 2018-01-01 2018-09-30 0001541884 LUNG:USFoodAndDrugAdministrationMember LUNG:OnOrBeforeJanuaryOneTwoThousandAndNineteenMember 2018-01-01 2018-09-30 0001541884 LUNG:USFoodAndDrugAdministrationMember LUNG:OnOrBeforeJanuaryOneTwoThousandAndTwentyMember 2018-01-01 2018-09-30 0001541884 2017-08-08 2017-08-09 0001541884 2017-09-30 0001541884 LUNG:StockOptionsMember 2018-01-01 2018-09-30 0001541884 LUNG:PlacementAgentMember LUNG:WarrantsMember 2018-09-30 0001541884 LUNG:DirectorsMember 2018-03-01 2018-03-31 0001541884 LUNG:ThroughSeptemberTwoThousandAndNineteenMember 2018-09-30 0001541884 LUNG:ThroughSeptemberTwoThousandAndNineteenMember 2018-01-01 2018-09-30 0001541884 us-gaap:ConvertibleNotesPayableMember 2017-12-31 0001541884 LUNG:StockOptionIncentivePlanMember 2018-09-30 0001541884 LUNG:BoardAndKeyEmployeeOptionGrantsMember 2018-09-30 0001541884 LUNG:StockOptionsMember 2017-01-01 2017-09-30 0001541884 2018-11-14 0001541884 2018-09-30 0001541884 2017-01-01 2017-09-30 0001541884 us-gaap:ConvertibleNotesPayableMember 2018-09-30 0001541884 LUNG:ConvertibleNotesPayableOneMember 2018-09-30 0001541884 LUNG:ConvertibleNotesPayableOneMember 2017-12-31 0001541884 LUNG:ConvertibleNotesMember 2018-09-30 0001541884 LUNG:ConvertibleNotesMember 2018-01-01 2018-09-30 0001541884 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001541884 LUNG:PrincipalMember 2018-01-01 2018-09-30 0001541884 LUNG:InterestMember 2018-01-01 2018-09-30 0001541884 LUNG:ConvertibleNotesMember srt:MinimumMember 2018-09-30 0001541884 LUNG:ConvertibleNotesMember srt:MaximumMember 2018-09-30 0001541884 LUNG:ThroughDecemberThirtyOneTwoThousandAndNineteenMember 2018-01-01 2018-09-30 0001541884 LUNG:WarrantsMember 2018-01-01 2018-09-30 0001541884 LUNG:WarrantsMember 2018-09-30 0001541884 us-gaap:ConvertibleNotesPayableMember 2018-01-01 2018-09-30 0001541884 us-gaap:ConvertibleNotesPayableMember 2017-01-01 2017-12-31 0001541884 LUNG:ConvertibleNotesPayableOneMember 2018-01-01 2018-09-30 0001541884 LUNG:ConvertibleNotesPayableOneMember 2017-01-01 2017-12-31 0001541884 LUNG:StockIncentivePlanMember LUNG:JanuaryOneTwoThousandAndTwentySevenMember 2017-07-31 0001541884 LUNG:BoardAndKeyEmployeeOptionGrantsMember 2018-01-01 2018-09-30 0001541884 LUNG:WarrantsMember 2017-01-01 2017-09-30 0001541884 us-gaap:MeasurementInputExercisePriceMember 2018-01-01 2018-09-30 0001541884 us-gaap:MeasurementInputPriceVolatilityMember 2018-01-01 2018-09-30 0001541884 us-gaap:MeasurementInputExpectedDividendRateMember 2018-01-01 2018-09-30 0001541884 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-01-01 2018-09-30 0001541884 2018-07-01 2018-09-30 0001541884 2017-07-01 2017-09-30 0001541884 LUNG:PlacementAgentMember LUNG:WarrantsMember 2018-01-01 2018-09-30 0001541884 us-gaap:ConvertibleDebtMember 2017-01-01 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember 2017-09-30 0001541884 LUNG:RelatedPartyNotesPayableMember 2017-01-01 2017-09-30 0001541884 LUNG:RelatedPartyNotesPayableMember 2017-09-30 0001541884 LUNG:ThirdPartyNoteMember 2017-09-30 0001541884 LUNG:ThirdPartyNoteMember 2017-01-01 2017-09-30 0001541884 LUNG:ThroughFebruaryTwoThousandandEighteenMember 2018-01-01 2018-09-30 0001541884 us-gaap:ConvertibleDebtMember us-gaap:ExecutiveOfficerMember 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember us-gaap:ExecutiveOfficerMember 2017-01-01 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember LUNG:RelatedPartyMember 2017-01-01 2017-09-30 0001541884 us-gaap:ConvertibleDebtMember LUNG:RelatedPartyMember 2017-09-30 0001541884 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001541884 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001541884 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001541884 LUNG:ChiefMedicalOfficerMember 2018-05-01 2018-05-31 0001541884 LUNG:BoardMembersMember 2018-05-01 2018-05-31 0001541884 LUNG:BoardAndKeyEmployeeOptionGrantsMember 2018-07-01 2018-09-30 0001541884 LUNG:WarrantsMember 2017-07-01 2017-09-30 0001541884 LUNG:IndividualRelatedToExecutiveOfficerMember 2017-09-30 0001541884 LUNG:IndividualRelatedToExecutiveOfficerMember 2017-01-01 2017-09-30 0001541884 us-gaap:MeasurementInputExpectedTermMember 2018-01-01 2018-09-30 0001541884 LUNG:BoardMembersMember 2018-01-01 2018-09-30 0001541884 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001541884 LUNG:StockOptionsMember 2018-07-01 2018-09-30 0001541884 LUNG:ConvertibleNotesMember 2018-07-01 2018-09-30 0001541884 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001541884 LUNG:StockOptionsMember 2017-07-01 2017-09-30 0001541884 LUNG:ConvertibleNotesMember 2017-07-01 2017-09-30 0001541884 LUNG:FromDecemberThirtyFirstToDecemberThirtyOneTwoThousandAndNineteenMember 2018-01-01 2018-09-30 0001541884 LUNG:DecemberThirtyOneTwoThousandAndNineteenEstimateMember 2018-01-01 2018-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PROLUNG INC 0001541884 10-Q 2018-09-30 false --12-31 Non-accelerated Filer Q3

0.001

10000000

0.001

120000000

500000

120000000

900000

3861848

40000

3861848

1021625

579754

441871

385013

70360

31990

261153

99129

-67139

261153

35446

Note 1 – Organization and Summary of Significant Accounting Policies   Organization   ProLung, Inc. (the “Company”), is a Delaware corporation that was incorporated on November 22, 2004 and is doing business as “ProLung.” The Company’s headquarters are located in Salt Lake City, Utah. The Company’s business is the marketing and sales of precision predictive analytical medical devices specializing in lung cancer. The Company’s principal activities are primarily developing products, seeking clearance by the U.S. Food and Drug Administration (the “FDA”) for its product, developing markets, securing strategic alliances and obtaining financing.   Principles of Consolidation   During the year ended December 31, 2012, the Company formed a wholly-owned subsidiary, Hilltop Acquisition Corporation, Inc., which has had no activity since its inception and is included in the accompanying condensed consolidated financial statements from the date of its formation.   Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared by management in accordance with rules and regulations promulgated by the U.S. Securities and Exchange Commission and therefore certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for them to be presented fairly, with those adjustments consisting only of normal recurring adjustments. These interim financial statements should be read in conjunction with the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K (the “Form 10-K”) for the year ended December 31, 2017. The results of operations for the three and nine months ended September 30, 2018 may not be indicative of the results to be expected for the year ending December 31, 2018.   Going Concern   The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated minimal revenues thus far from its operations. The Company will not reach its planned level of operations in the United States until it receives FDA approval, if ever. The Company does have a CE mark for Europe and has licensed a portion of its technology to an entity located in China. The Company’s focus and use of funds during 2017 and the first nine months of 2018 has been on obtaining FDA approval and building an infrastructure to launch the United States market. The Company has incurred substantial and recurring losses to date from operations, continues to have a stockholders’ deficit and is currently dependent on debt and equity financing. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result relating to the recoverability and classification of the asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this risk and uncertainty.   The ability of the Company to continue as a going concern is dependent on the Company successfully obtaining additional funding, developing products that can be sold profitably, and generating cash through operating activities. Management’s plans include issuing equity or debt securities to fund capital requirements and developing ongoing operations. See Note 4 for funds raised from a convertible note offering. However, there can be no assurance the Company will raise sufficient funds and be successful in raising sufficient funds to continue as a going concern.   Basic and Diluted Loss Per Share   The Company computes basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company computes diluted loss per share by dividing net loss by the sum of the weighted-average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of diluted loss per share does not assume exercise or conversion of securities that would have an anti-dilutive effect. As of September 30, 2018, and 2017, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">For the Three and Nine Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Warrants to purchase shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1,231,559</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1,205,623</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">283,417</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">127,500</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible notes</td> <td> </td> <td> </td> <td style="text-align: right">698,919</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">201,155</td> <td> </td></tr> </table>   Convertible Debt   The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt that has conversion features at fixed or adjustable rates that are in-the-money when issued. The BCF for the convertible instruments is recognized equal to the intrinsic value of the conversion features which is credited to additional paid-in capital.   Adoption of New Accounting Policies   In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that restricted cash and cash equivalents be included as components of total cash and cash equivalents as presented on the statement of cash flows. ASU 2016-18 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and a retrospective transition method is required. The Company adopted this guidance in the first quarter of 2018 but has not historically had restricted cash resulting in no impact to previously reported periods.   Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), as amended. These new standards supersede all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The Company does not, at this time, expect it to have a material impact on the Company’s revenue recognition. However, the Company does expect to have significant changes to the footnote disclosures related to revenue recognition as a result of implementing these new standards. As the Company has elected to be treated as an emerging growth company, this standard will be implemented effective January 1, 2019.   In February 2016, the FASB issued ASU No. 2016-02: Leases. ASU 2016-02 requires companies to generally recognize on the balance sheet, operating and financing lease liabilities and corresponding right-of-use assets. ASU 2016-02 will be effective for the Company’s fiscal year beginning January 1, 2020 on a modified retrospective basis and earlier adoption is permitted. Management is currently evaluating the impact of the pending adoption of ASU 2016-02 and based on the Company’s one lease agreement, does not anticipate a material impact to the condensed consolidated financial statements.   In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II). Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within current account guidance with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted. The Company has not had any instruments that meet the criteria for Part I, but could issue such instruments in the future; therefore, the Company is currently evaluating the impact that the adoption of the standard could have on its future condensed consolidated financial statements.   ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities was issued in August 2017. The amendments under ASU 2017-12, refine and expand hedge accounting requirements for both financial (e.g., interest rate) and commodity risks. Its provisions create more transparency around how economic results are presented, both on the face of the financial statements and in the footnotes. It also makes certain targeted improvements to simplify the application of hedge accounting guidance. The standard is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company will adopt this ASU on January 1, 2020. The Company does not currently have any derivative or hedging instruments but may in the future.   In June 2018, the FASB issued ASU 2018-07 Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018; Early adoption is permitted, but no earlier than the Company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company does not currently have any stock options to non-employees that have a vesting requirement. However, if the Company were to issue options to a non-employee with a vesting provision the implementation of this standard would provide a consistent expense over the service period of the non-employee.   In August 2018, the FASB issued ASU 2018-13, Changes to Disclosure Requirements for Fair Value Measurements, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact that the adoption of the standard could have on its future condensed consolidated financial statements.

Note 3 – Accrued Liabilities   Accrued liabilities consisted of the following at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; line-height: 107%">Accrued interest</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">151,770</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accrued royalties</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accrued payroll and payroll taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">58,868</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,529</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total Accrued Liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">228,511</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">25,402</td> <td style="line-height: 107%"> </td></tr> </table>

Note 4 –Notes Payable   2018 Transactions   In March 2018, the Company began issuing 8% convertible promissory notes (“convertible notes”). The convertible notes are unsecured. Principal and accrued interest are due two years from the date of issuance. The holder of the convertible note is entitled, at its option, to convert all, or any portion of the outstanding principal and interest, into shares of the Company’s common stock at a conversion price of $6.30 per share. Interest accruing from the date of issuance to the conversion date shall be paid on the maturity date. If the Company completes a public offering of its common stock, the convertible promissory notes and accrued interest automatically convert into common stock at the lower of i) 90% of the public offering price or ii) $6.30 per share.   During the nine months ended September 30, 2018, the Company issued $2,982,750 in convertible promissory notes and accrued interest totaling $127,631 which would be convertible into 493,740 shares of common stock (473,467 shares for principal and 20,273 shares for interest).   On the date the convertible notes were issued, the fair value of the Company’s stock was estimated to be $7.28 per share which was greater than the conversion rate of $6.30. The $0.98 per share difference is considered a beneficial conversion feature. The beneficial conversion feature related to the convertible notes was $463,983. On the date of issuance, the Company also assessed the conversion feature for possible derivative treatment (under ASC 815) and determined the conversion feature was indexed to the Company’s common stock and thus not a derivative.   The Company utilized a placement agent in connection with the offering which entitled them to a cash commission of 10% of the convertible notes issued, $25,000 for non-accountable expenses and warrants to purchase 10% of the potential conversion shares of stock associated with the principal portion of convertible notes issued by the Company (47,186 warrants). Pursuant to this agreement, the Company incurred cash commission fees to the placement agent of $322,275. The value of the 47,186 warrants was $275,321 ($5.83 per warrant), derived utilizing the Black-Scholes Pricing Model with the following weighted average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected life</td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%">2.5 years</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 80%; line-height: 107%">Exercise price</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">7.29</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">160</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividends</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">n/a</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.35</td> <td style="line-height: 107%">%</td></tr> </table>    The $597,596 in loan costs incurred was added to the $463,983 beneficial conversion feature creating a debt discount (“discount”) of $1,061,579. The accompanying condensed consolidated balance sheet reflects the convertible notes net of the discount. The discount will be amortized as a component of interest expense over the term of the convertible notes. During the three and nine months ended September 30, 2018, the Company recognized interest expense of $133,977 and $274,758 related to the amortization of the beneficial conversion feature and loan costs. As of September 30, 2018, the unamortized balance of the beneficial conversion feature and loan costs is $786,821.   2017 Transactions   During the nine months ended September 30, 2017 convertible debentures were converted or repaid as follows: The Company repaid $164,000 in principal along with $25,700 in related accrued interest. The remaining convertible debenture holders elected to convert $1,093,050 in principal along with $162,739 in related interest into 241,500 shares of common stock at a rate of $5.20 per share.   During the nine months ended September 30, 2017, $89,389 of principal of a master note to an individual related to an executive officer of the Company was repaid along with interest of $39,071. In addition, the noteholder elected to convert the remaining $100,000 of principal for 8,334 shares of common stock as well as 8,334 warrants to purchase stock at a price of $12.00 per unit.   During the nine months ended September 30, 2017, $105,000 of related-party notes were repaid along with interest and fees of $5,000. The Company repaid $50,000 in cash, and the individual elected to convert the remaining $60,000 into 5,000 shares of common stock, and 5,000 warrants to purchase stock, at a price of $12 per share. During the nine months ended September 30, 2017, the same individual made a short-term advance of $35,000 that did not bear interest which was repaid during the nine months ended September 30, 2017.   During the nine months ended September 30, 2017, $32,000 of principal along with $1,185 of related accrued interest for a third-party note was repaid with cash.   Notes payable are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Convertible notes payable net of $786,821 in discount and loan costs; unsecured; interest at 8.00%; due March through May 2020</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">2,195,929</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes payable; unsecured; interest at 8.00%; due November 2020</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Notes payable</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,402,860</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td></tr> </table>

Note 5 – Common Stock   Public Offering of Common Stock of the Company   During 2017 through February 2018, the Company filed a Registration Statement and subsequent amendments on Form S-1 (the “Registration Statement”). The Registration Statement related to a potential public offering of the Company’s common stock. There was no assurance that any shares would be offered and sold pursuant to such Registration Statement. Through February 2018, the Company incurred cash offering costs totaling $303,401 which were to be offset against the proceeds received if such offering was completed. In February 2018, the Board suspended the offering, and in June 2018, the Board decided not to pursue the public offering in the near future and the Company wrote-off the deferred offering costs to expense.   Private Placement of Common Stock of the Company   During 2016 and through May 2017, the Company issued equity under a private placement agreement. The Company engaged two separate placement agents during different time periods in connection with the offering, which placement agents were entitled to a cash commission of ten percent of the issuance price of the common stock sold in the offering, and one share of common stock of the Company for each ten shares of the Company’s common stock sold in the offering. Pursuant to these agreements, the Company had incurred commission fees to the placement agents of $826,146 together with 67,326 shares of common stock as of September 30, 2017. For the nine months ended September 30, 2017, the Company received subscriptions for $6,531,567 and paid $664,452 of cash offering costs. As of September 30, 2017, the total adjusted maximum offering amount of $8.2 million was subscribed for and the offering was closed.   Common Stock Issued for Conversion of Convertible Notes and Debentures   During the nine months ended September 30, 2017 the following conversions occurred:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">$1,093,050 of convertible debentures and $162,739 of accrued interest was converted at $5.20 per share into 241,500 shares of common stock;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">As partial settlement of a note payable to a relative of an Executive Officer, $100,000 was converted at $12.00 per share into 8,334 shares of common stock;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">As partial settlement of a related party note, $55,000 of principal and $5,000 of interest was converted at $12.00 per share into 5,000 shares of common stock.</td></tr> </table>   Common Stock Issued for Services   During the nine months ended September 30, 2017, the Company issued 6,250 shares of common stock with a total value of $53,500 to certain Board members and consultants for services rendered.   Total stock-based compensation expense from all sources for the three and nine months ended September 30, 2018 and 2017, including stock-based compensation for the options and warrants discussed in Note 6 and Note 7, has been included in the condensed consolidated statements of operations as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%">Research and development expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">99,129</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">579,754</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Selling, general and administrative expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(67,139</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">261,153</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">441,871</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">385,013</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total share-based compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">31,990</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">261,153</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,021,625</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">385,013</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Note 7 – Common Stock Warrants   A summary of warrant activity for the nine months ended September 30, 2018 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Value of</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Under</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Vested</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Outstanding at December 31, 2017</td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">1,184,998</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">9.16</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">1.9 years</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">1,160,404</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">47,186</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">7.29</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Expired/Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(625</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.01</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,231,559</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">9.02</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.1 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1,155,860</td> <td style="line-height: 107%"> </td></tr> </table>   The intrinsic value at September 30, 2018 is calculated at $7.28 per share less the exercise price, based on management’s latest estimate of the fair value of the shares of common stock, which is the latest price the Company has issued shares of common stock for cash.   The Company recognized $35,446 and $70,360 as share-based compensation related to the vesting of warrant shares for the three and nine months ended September 30, 2017, respectively.

As of September 30, 2018, and 2017, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Three and Nine Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; line-height: 107%">Warrants to purchase shares</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 18%; text-align: right; line-height: 107%">1,231,559</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">1,205,623</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Stock options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">283,417</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">127,500</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">698,919</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">201,155</td> <td style="line-height: 107%"> </td></tr> </table>

Inventory consists of the following at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Raw materials</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">73,415</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">66,417</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Work in progress</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">13,340</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">12,465</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Finished goods</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">176,332</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">176,755</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total inventory</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">263,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">255,637</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less: carrying value of inventory not deemed to be a current asset</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">  263,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">  255,637</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Inventory, included in current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

Accrued liabilities consisted of the following at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; line-height: 107%">Accrued interest</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">151,770</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accrued royalties</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">17,873</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accrued payroll and payroll taxes</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">58,868</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">7,529</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total Accrued Liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">228,511</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">25,402</td> <td style="line-height: 107%"> </td></tr> </table>

Total stock-based compensation expense from all sources for the three and nine months ended September 30, 2018 and 2017, including stock-based compensation for the options and warrants discussed in Note 6 and Note 7, has been included in the condensed consolidated statements of operations as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%">Research and development expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">99,129</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">579,754</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Selling, general and administrative expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(67,139</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">261,153</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">441,871</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">385,013</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total share-based compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">31,990</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">261,153</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,021,625</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">385,013</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of warrant activity for the nine months ended September 30, 2018 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Intrinsic</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Value of</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Under</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Contractual</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Vested</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Outstanding at December 31, 2017</td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">1,184,998</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">9.16</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">1.9 years</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 3%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">1,160,404</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">47,186</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">7.29</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Expired/Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(625</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.01</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,231,559</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">9.02</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.1 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1,155,860</td> <td style="line-height: 107%"> </td></tr> </table>

Note 6 – Common Stock Options   Equity Incentive Plan   In July 2017, the shareholders approved the ProLung, Inc. Stock Incentive Plan (the “Plan”). The Plan authorizes the Board’s Compensation Committee to grant incentive stock options, non-incentive stock options, stock bonuses, restricted stock, and performance-based awards to directors, officers and employees and non-employee agents, consultants, advisers and independent contractors of the Company or any parent or subsidiary of the Company.   The total number of initial shares of Common Stock authorized for issuance under the Plan is 500,000 shares. The authorized shares will automatically increase on January 1 of each year, for ten consecutive years, commencing on January 1, 2018, by the lesser of (i) 40,000 shares of Common Stock (i.e., 8% of the shares originally authorized to be issued), or (ii) such number of shares of common stock (if any) the Board may earlier designate in writing. If the automatic increases are not limited by the Board, there will be 900,000 shares of common stock authorized under the Plan in January 1, 2027.   Board and Key Employee Option Grants   In March 2018, the Board’s compensation committee approved the issuance of 938 options to a new director of the Company at an exercise price of $8 per option. One third of the options vest immediately with the remaining two thirds vesting at June 30, 2018. The fair value of these options was $6.18 per option or $5,794 and will be expensed over the relative vesting period.   In May 2018, as part of a bonus agreement the Board approved the issuance of 30,000 options to our Chief Medical Officer with an exercise price of $8 per option. These options vested upon issuance. The fair value of these options was $6.28 per option or $188,289 and was expensed upon issuance.   At a Board meeting in May 2018, the Board approved the issuance of stock options as payment for their 2018 Board fees in lieu of cash which included the first quarter accrual of $105,500. The Company issued 50,016 options to these Board members with one third vesting immediately, one third vesting on June 30, 2018 and the remaining one third vesting on September 30, 2018. The fair value of these options was $6.07 per option or $303,696, were expensed over the relative vesting period and are fully vested at September 30, 2018   During the nine months ended September 30, 2018, certain employees separated from the Company and several directors resigned resulting in 48,893 options being forfeited and $140,303 of future expense being eliminated.   The fair value was computed using the Black Scholes method using the following weighted-average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected life</td> <td> </td> <td colspan="2" style="text-align: right">5.06 Years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">8.00</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">125</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividends</td> <td> </td> <td> </td> <td style="text-align: right">None</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk-free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">2.81</td> <td>%</td></tr> </table>   The Company recorded an expense of $227,262 and $1,049,054 for the three and nine months ended September 30, 2018, respectively, related to the amortization of options issued under the Plan. The remaining unrecognized expense of $162,488 will be recognized through September 30, 2019 with a weighted average term of 1.0 years.   CEO Stock Option Incentive   The Company granted the Company’s former CEO stock option incentives related to FDA approval. The stock option shall expire 10 years after the grant date and shall vest with respect to a number of options of Common Stock upon the receipt of FDA marketing authorization (as defined below), with such number of options to be as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">112,500 options if FDA marketing authorization is obtained after January 1, 2018 and on or before July 1, 2018;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">75,000 options if FDA marketing authorization is obtained after July 1, 2018 and on or before January 1, 2019;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">37,500 options if FDA marketing authorization is obtained after January 1, 2019 and on or before January 1, 2020.</td></tr> </table>   The Company considered these options to be performance based with August 9, 2017 the grant date. Solely for accounting purposes, the Company originally estimated the conditions for vesting will be met between July and December 2018. Based on this estimate, management believed the most probable number of options to be issued would be 75,000, less a pro-rata reduction due to the CEO’s separation from the Company.   During the three months ended September 30, 2018, the Company concluded it was improbable that FDA marketing authorization would be obtained by December 31, 2018. The Company updated their estimate whereby the conditions for vesting will likely be met by December 31, 2019. Based on the December 31, 2019 estimate, the number of options decreased from 75,000 to 37,500 (less a pro-rata reduction due the CEO’s separation from the Company) and the resulting value from $472,000 to $223,000; as the service period was extended from December 31, 2018 to December 31, 2019. Through the date of the change in estimate, the Company had amortized $301,375 of compensation expense related to the original estimate. Based on the updated estimate the Company should have amortized $106,103 of compensation expense. As a result, the Company recognized a net reversal of compensation expense of $195,272 and $27,429 for the three and nine months ended September 30, 2018, respectively. The remaining $116,281 is being recognized through December 31, 2019, less a pro-rata reduction due to the CEO’s separation from the Company.   As of September 30, 2018, there are currently 178,293 options available for issuance under the Plan.   A summary of option activity for the nine months ended September 30, 2018 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Aggregate</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Intrinsic</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Value of</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Under</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Contractual</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Vested</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Life</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Outstanding at December 31, 2017</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">331,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">8.05</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">10.0 years</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">                -</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Issued</td> <td> </td> <td> </td> <td style="text-align: right">80,954</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Adjustment</td> <td> </td> <td> </td> <td style="text-align: right">(37,500</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited/Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(91,037</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">8.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">283,417</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">8.00</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">9.28 years</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Vested at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">195,198</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">8.00</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">9.22 years</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The fair value was computed using the Black Scholes method using the following weighted-average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected life</td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%">5.06 Years</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 80%; line-height: 107%">Exercise price</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">8.00</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">125</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividends</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">None</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.81</td> <td style="line-height: 107%">%</td></tr> </table>

A summary of option activity for the nine months ended September 30, 2018 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Aggregate</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Intrinsic</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Value of</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Under</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Contractual</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Vested</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Life</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Outstanding at December 31, 2017</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">331,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">8.05</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">10.0 years</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">                -</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Issued</td> <td> </td> <td> </td> <td style="text-align: right">80,954</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Adjustment</td> <td> </td> <td> </td> <td style="text-align: right">(37,500</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">8.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited/Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(91,037</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">8.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">283,417</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">8.00</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">9.28 years</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Vested at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">195,198</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">8.00</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">9.22 years</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

1206931

3402860

2195929

1206931

3861848

66417

73415

12465

13340

176755

176332

255637

263087

255637

263087

7.28

1093050

60000

100000

55000

127631

162739

5000

0.98

6.30

5.20

12.00

80954

112500

75000

37500

75000

938

30000

50016

1231559

698919

1205623

201155

283417

127500

1231559

283417

698919

1205623

127500

201155

151770

17873

7529

58868

597596

105000

32000

89389

0.0800

0.10

0.0800

0.08

285389

50000

25700

5000

162739

47186

5000

8334

Due March through May 2020

Due November 2020

0.08

8.00

1049054

227262

162488

P10Y

P1Y

331000

283417

7.28

1184998

1231559

47186

-625

9.16 9.02 7.29 0.01 P1Y10M25D P1Y1M6D 1160404 1155860

178293

Note 2 – Inventory   Inventory principally consists of the cost of materials purchased and assembled. The cost of inventory also includes the costs of direct labor for the assembly and certain indirect costs incurred in connection with purchasing of parts and the assembly of products. Inventory consists of the following at September 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%">Raw materials</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">73,415</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">66,417</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Work in progress</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">13,340</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">12,465</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Finished goods</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">176,332</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">176,755</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total inventory</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">263,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">255,637</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less: carrying value of inventory not deemed to be a current asset</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">  263,087</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">  255,637</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Inventory, included in current assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

Notes payable are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%">Convertible notes payable net of $786,821 in discount and loan costs; unsecured; interest at 8.00%; due March through May 2020</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">2,195,929</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes payable; unsecured; interest at 8.00%; due November 2020</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Notes payable</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">3,402,860</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,206,931</td> <td style="line-height: 107%"> </td></tr> </table>

LUNG

2982750

493740

473467

20273

241500

5000

8334

463983

0.90 0.10

786821

1061579

35000

5.83

12.00

100000

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected life</td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%">2.5 years</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 80%; line-height: 107%">Exercise price</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">7.29</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">160</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected dividends</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">n/a</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk-free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.35</td> <td style="line-height: 107%">%</td></tr> </table>

Organization   ProLung, Inc. (the “Company”), is a Delaware corporation that was incorporated on November 22, 2004 and is doing business as “ProLung.” The Company’s headquarters are located in Salt Lake City, Utah. The Company’s business is the marketing and sales of precision predictive analytical medical devices specializing in lung cancer. The Company’s principal activities are primarily developing products, seeking clearance by the U.S. Food and Drug Administration (the “FDA”) for its product, developing markets, securing strategic alliances and obtaining financing.

Principles of Consolidation   During the year ended December 31, 2012, the Company formed a wholly-owned subsidiary, Hilltop Acquisition Corporation, Inc., which has had no activity since its inception and is included in the accompanying condensed consolidated financial statements from the date of its formation.

Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared by management in accordance with rules and regulations promulgated by the U.S. Securities and Exchange Commission and therefore certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments necessary for them to be presented fairly, with those adjustments consisting only of normal recurring adjustments. These interim financial statements should be read in conjunction with the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K (the “Form 10-K”) for the year ended December 31, 2017. The results of operations for the three and nine months ended September 30, 2018 may not be indicative of the results to be expected for the year ending December 31, 2018.

Going Concern   The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated minimal revenues thus far from its operations. The Company will not reach its planned level of operations in the United States until it receives FDA approval, if ever. The Company does have a CE mark for Europe and has licensed a portion of its technology to an entity located in China. The Company’s focus and use of funds during 2017 and the first nine months of 2018 has been on obtaining FDA approval and building an infrastructure to launch the United States market. The Company has incurred substantial and recurring losses to date from operations, continues to have a stockholders’ deficit and is currently dependent on debt and equity financing. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result relating to the recoverability and classification of the asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this risk and uncertainty.   The ability of the Company to continue as a going concern is dependent on the Company successfully obtaining additional funding, developing products that can be sold profitably, and generating cash through operating activities. Management’s plans include issuing equity or debt securities to fund capital requirements and developing ongoing operations. See Note 4 for funds raised from a convertible note offering. However, there can be no assurance the Company will raise sufficient funds and be successful in raising sufficient funds to continue as a going concern.

Basic and Diluted Loss Per Share   The Company computes basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. The Company computes diluted loss per share by dividing net loss by the sum of the weighted-average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of diluted loss per share does not assume exercise or conversion of securities that would have an anti-dilutive effect. As of September 30, 2018, and 2017, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">For the Three and Nine Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; line-height: 107%">Warrants to purchase shares</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 18%; text-align: right; line-height: 107%">1,231,559</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">1,205,623</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Stock options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">283,417</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">127,500</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Convertible notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">698,919</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">201,155</td> <td style="line-height: 107%"> </td></tr> </table>

Convertible Debt   The Company records a beneficial conversion feature (“BCF”) related to the issuance of convertible debt that has conversion features at fixed or adjustable rates that are in-the-money when issued. The BCF for the convertible instruments is recognized equal to the intrinsic value of the conversion features which is credited to additional paid-in capital.

Adoption of New Accounting Policies   In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which requires that restricted cash and cash equivalents be included as components of total cash and cash equivalents as presented on the statement of cash flows. ASU 2016-18 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and a retrospective transition method is required. The Company adopted this guidance in the first quarter of 2018 but has not historically had restricted cash resulting in no impact to previously reported periods.

Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), as amended. These new standards supersede all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The Company does not, at this time, expect it to have a material impact on the Company’s revenue recognition. However, the Company does expect to have significant changes to the footnote disclosures related to revenue recognition as a result of implementing these new standards. As the Company has elected to be treated as an emerging growth company, this standard will be implemented effective January 1, 2019.   In February 2016, the FASB issued ASU No. 2016-02: Leases. ASU 2016-02 requires companies to generally recognize on the balance sheet, operating and financing lease liabilities and corresponding right-of-use assets. ASU 2016-02 will be effective for the Company’s fiscal year beginning January 1, 2020 on a modified retrospective basis and earlier adoption is permitted. Management is currently evaluating the impact of the pending adoption of ASU 2016-02 and based on the Company’s one lease agreement, does not anticipate a material impact to the condensed consolidated financial statements.   In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II). Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within current account guidance with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is effective for the Company for annual reporting periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted. The Company has not had any instruments that meet the criteria for Part I, but could issue such instruments in the future; therefore, the Company is currently evaluating the impact that the adoption of the standard could have on its future condensed consolidated financial statements.   ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities was issued in August 2017. The amendments under ASU 2017-12, refine and expand hedge accounting requirements for both financial (e.g., interest rate) and commodity risks. Its provisions create more transparency around how economic results are presented, both on the face of the financial statements and in the footnotes. It also makes certain targeted improvements to simplify the application of hedge accounting guidance. The standard is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The Company will adopt this ASU on January 1, 2020. The Company does not currently have any derivative or hedging instruments but may in the future.   In June 2018, the FASB issued ASU 2018-07 Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018; Early adoption is permitted, but no earlier than the Company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company does not currently have any stock options to non-employees that have a vesting requirement. However, if the Company were to issue options to a non-employee with a vesting provision the implementation of this standard would provide a consistent expense over the service period of the non-employee.   In August 2018, the FASB issued ASU 2018-13, Changes to Disclosure Requirements for Fair Value Measurements, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact that the adoption of the standard could have on its future condensed consolidated financial statements.

6.18

6.28

6.07

5794

188289

303696

2018 7.29 1.60 0.00 0.0235

303401

8200000

274758

133977

1185

39071

25000

275321

786821

664452

303401

826146 67326

6531567

241500

8334

5000

75000

6250

472000

53500

105500 48893 140303

P5Y0M22D

8.00

1.25

0.00

0.0281

91037

195198

8.05

8.00

P10Y

P9Y3M11D

P9Y2M19D

true true false

636639

720915

31844

12173

971884

733088

255637

263087

81378

53680

156176

149005

1465075

1198860

295918

216660

25402

228511

321320

445171

1206931

3402860

1528251

3799520

3862

21387907

23148836

-21454945

-25801869

-63176

-2649171

1465075

1198860

3861848

3522810

3861848

3849791

-1.13

-1.02

-0.26

-0.35

-4346924

-3605831

-991617

-1366120

476589

97957

216790

24211

303401

-3566934

-3507874

-774827

-1341909

3566934

3507874

774827

1341909

2042167

2472940

361876

1067502

1524767

1034934

412951

274407

29624

24195

3294

-690

7450

22906

-19671

12150

-79258

-163520

203109

-32282

-2584738

-3426791

8539

394

19842

8539

-19448

6531567

322275 995412

2982750

35000

85000

2660475

5200766

84276

1754527

636639

28922

1783449

720915

48277

169623

463983 275321 1355789 60000 P2Y6M -37500 8.00 37500 223000 The service period was extended from December 31, 2018 to December 31, 2019. 322275

164000

25700

116281 301375 106103 27429 195272

EX-101.SCH 5 lung-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Common Stock Options link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Common Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Common Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Notes Payable - Schedule of Weighted Average Assumptions Using Black-Scholes Model (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Common Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Common Stock Options - Summary of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Common Stock Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Common Stock Warrants - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 lung-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 lung-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 lung-20180930_lab.xml XBRL LABEL FILE Income Statement Location [Axis] Research and Development Expense [Member] Selling, General and Administrative Expenses [Member] Equity Components [Axis] Warrants [Member] Warrant to Purchase Shares [Member] Convertible Notes [Member] Board and Key Employee Option Grants [Member] Plan Name [Axis] Stock Incentive Plan [Member] Related Party [Axis] U.S. Food and Drug Administration [Member] Report Date [Axis] On or Before July 1, 2018 [Member] On or Before January 1, 2019 [Member] On or Before January 1, 2020 [Member] Stock Options [Member] Title of Individual [Axis] Placement Agent [Member] Directors [Member] Through September 2019 [Member] Debt Instrument [Axis] Convertible Notes Payable [Member] Stock Option Incentive Plan [Member] Convertible Notes Payable 1 [Member] Common Stock [Member] Principal [Member] Interest [Member] Range [Axis] Minimum [Member] Maximum [Member] Through December 31, 2019 [Member] January 1, 2027 [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Measurement Input Type [Axis] Exercise Price [Member] Expected Volatility [Member] Expected Dividend [Member] Risk Free Interest Rate [Member] Short-term Debt, Type [Axis] Convertible Debentures [Member] Related-Party Notes Payable [Member] Third-Party Note [Member] Through February 2018 [Member] Executive Officer [Member] Related Party [Member] Chief Medical Officer [Member] Board Members [Member] Individual Related to Executive Officer [Member] Expected Life [Member] From December 31, 2018 to December 31, 2019 [Member] December 31, 2019 Estimate [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash Prepaid expenses Deferred offering costs Total Current Assets Inventory, noncurrent Property and equipment, net of accumulated depreciation Intangible assets, net of accumulated amortization Total Assets Liabilities and Stockholders' Deficit Current Liabilities Accounts payable Accrued liabilities Total Current Liabilities Long-Term Liabilities Notes payable, net of discount Total Long-Term Liabilities Total Liabilities Stockholders' Deficit: Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding Common stock, $0.001 par value; 120,000,000 shares authorized; 3,861,848 shares issued and outstanding Additional paid-in capital Accumulated deficit Total Stockholders' Deficit Total Liabilities and Stockholders' Deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues: Revenue Total revenue Cost of revenue Gross margin Operating expenses: Research and development expense Selling, general and administrative expense Total operating expenses Loss from operations Other income (expense): Write-off of deferred offering costs Interest expense Net loss Basic and diluted loss per share Weighted-average common shares outstanding, basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash flows from operating activities: Depreciation and amortization (Gain) loss on sale of equipment Amortization of loan discount Stock-based compensation Write-off of deferred offering costs Change in assets and liabilities: Inventory Prepaid expenses Accounts payable Accrued liabilities Net cash flows from operating activities Cash flows from investing activities: Proceeds from sale of equipment Payments for equipment Net cash flows from investing activities Cash flows from financing activities: Proceeds from issuance of common stock and warrants Payment for loan and stock offering costs Payment on notes payable and convertible debentures Proceeds from notes payable Proceeds from related party notes payable Payment on related party notes payable Net cash flows from financing activities Net increase in cash Cash at beginning of period Cash at end of period Supplemental disclosure of cash flow information: Cash paid for income taxes Cash paid for interest Supplemental disclosure of non-cash investing and financing activities: Beneficial conversion feature Warrants issued to placement agent Conversion of convertible debt and interest Conversion of related party debt and interest Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Inventory Disclosure [Abstract] Inventory Payables and Accruals [Abstract] Accrued Liabilities Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Common Stock Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Common Stock Options Common Stock Warrants Organization Principles of Consolidation Basis of Presentation Going Concern Basic and Diluted Loss Per Share Convertible Debt Adoption of New Accounting Policies Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Inventory Schedule of Accrued Liabilities Schedule of Weighted Average Assumptions Using Black-Scholes Model Schedule of Notes Payable Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan Schedule of Fair Value of Options Grants Using Black Scholes Method Summary of Option Activity Schedule of Warrant Activity Statement [Table] Statement [Line Items] Antidilutive securities excluded from computation of earnings per share Raw materials Work in progress EX-101.PRE 9 lung-20180930_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 14, 2018
Document And Entity Information
Entity Registrant Name	PROLUNG INC
Entity Central Index Key	0001541884
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		3,861,848
Trading Symbol	LUNG
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets
Cash	$ 720,915	$ 636,639
Prepaid expenses	12,173	31,844
Deferred offering costs		303,401
Total Current Assets	733,088	971,884
Inventory, noncurrent	263,087	255,637
Property and equipment, net of accumulated depreciation	53,680	81,378
Intangible assets, net of accumulated amortization	149,005	156,176
Total Assets	1,198,860	1,465,075
Current Liabilities
Accounts payable	216,660	295,918
Accrued liabilities	228,511	25,402
Total Current Liabilities	445,171	321,320
Long-Term Liabilities
Notes payable, net of discount	3,402,860	1,206,931
Total Long-Term Liabilities	3,402,860	1,206,931
Total Liabilities	3,799,520	1,528,251
Stockholders' Deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 120,000,000 shares authorized; 3,861,848 shares issued and outstanding	3,862	3,862
Additional paid-in capital	23,148,836	21,387,907
Accumulated deficit	(25,801,869)	(21,454,945)
Total Stockholders' Deficit	(2,649,171)	(63,176)
Total Liabilities and Stockholders' Deficit	$ 1,198,860	$ 1,465,075

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	3,861,848	3,861,848
Common stock, shares outstanding	3,861,848	3,861,848

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Revenue
Total revenue
Cost of revenue
Gross margin
Operating expenses:
Research and development expense	412,951	274,407	1,524,767	1,034,934
Selling, general and administrative expense	361,876	1,067,502	2,042,167	2,472,940
Total operating expenses	774,827	1,341,909	3,566,934	3,507,874
Loss from operations	(774,827)	(1,341,909)	(3,566,934)	(3,507,874)
Other income (expense):
Write-off of deferred offering costs			(303,401)
Interest expense	(216,790)	(24,211)	(476,589)	(97,957)
Net loss	$ (991,617)	$ (1,366,120)	$ (4,346,924)	$ (3,605,831)
Basic and diluted loss per share	$ (0.26)	$ (0.35)	$ (1.13)	$ (1.02)
Weighted-average common shares outstanding, basic and diluted	3,861,848	3,849,791	3,861,848	3,522,810

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (4,346,924)	$ (3,605,831)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	29,624	24,195
(Gain) loss on sale of equipment	(3,294)	690
Amortization of loan discount	274,758
Stock-based compensation	1,021,625	385,013
Write-off of deferred offering costs	303,401
Change in assets and liabilities:
Inventory	(7,450)	(22,906)
Prepaid expenses	19,671	(12,150)
Accounts payable	(79,258)	(163,520)
Accrued liabilities	203,109	(32,282)
Net cash flows from operating activities	(2,584,738)	(3,426,791)
Cash flows from investing activities:
Proceeds from sale of equipment	8,539	394
Payments for equipment		(19,842)
Net cash flows from investing activities	8,539	(19,448)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants		6,531,567
Payment for loan and stock offering costs	(322,275)	(995,412)
Payment on notes payable and convertible debentures		(285,389)
Proceeds from notes payable	2,982,750
Proceeds from related party notes payable		35,000
Payment on related party notes payable		(85,000)
Net cash flows from financing activities	2,660,475	5,200,766
Net increase in cash	84,276	1,754,527
Cash at beginning of period	636,639	28,922
Cash at end of period	720,915	1,783,449
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	48,277	169,623
Supplemental disclosure of non-cash investing and financing activities:
Beneficial conversion feature	463,983
Warrants issued to placement agent	275,321
Conversion of convertible debt and interest		1,355,789
Conversion of related party debt and interest		$ 60,000

XML 15 R6.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

Note 1 – Organization and Summary of Significant Accounting Policies

Organization

Principles of Consolidation

Basis of Presentation

Going Concern

Basic and Diluted Loss Per Share

	For the Three and Nine Months Ended
	September 30,
	2018		2017
Warrants to purchase shares		1,231,559		1,205,623
Stock options		283,417		127,500
Convertible notes		698,919		201,155

Convertible Debt

Adoption of New Accounting Policies

Recent Accounting Pronouncements

XML 16 R7.htm IDEA: XBRL DOCUMENT

Inventory

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Inventory

Note 2 – Inventory

	September 30, 2018		December 31, 2017

Raw materials	$	73,415	$	66,417
Work in progress		13,340		12,465
Finished goods		176,332		176,755

Total inventory		263,087		255,637
Less: carrying value of inventory not deemed to be a current asset		263,087		255,637

Inventory, included in current assets	$	-	$	-

XML 17 R8.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

9 Months Ended

Sep. 30, 2018

Payables and Accruals [Abstract]

Accrued Liabilities

Note 3 – Accrued Liabilities

Accrued liabilities consisted of the following at September 30, 2018 and December 31, 2017:

	September 30, 2018		December 31, 2017

Accrued interest	$	151,770	$	-
Accrued royalties		17,873		17,873
Accrued payroll and payroll taxes		58,868		7,529

Total Accrued Liabilities	$	228,511	$	25,402

XML 18 R9.htm IDEA: XBRL DOCUMENT

Notes Payable

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Notes Payable

Note 4 –Notes Payable

2018 Transactions

Expected life	2.5 years
Exercise price	$	7.29
Expected volatility		160	%
Expected dividends		n/a
Risk-free interest rate		2.35	%

2017 Transactions

During the nine months ended September 30, 2017, $32,000 of principal along with $1,185 of related accrued interest for a third-party note was repaid with cash.

Notes payable are summarized as follows:

	September 30, 2018		December 31, 2017
Convertible notes payable net of $786,821 in discount and loan costs; unsecured; interest at 8.00%; due March through May 2020	$	2,195,929	$	-

Convertible notes payable; unsecured; interest at 8.00%; due November 2020		1,206,931		1,206,931

Notes payable	$	3,402,860	$	1,206,931

XML 19 R10.htm IDEA: XBRL DOCUMENT

Common Stock

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Common Stock

Note 5 – Common Stock

Public Offering of Common Stock of the Company

Private Placement of Common Stock of the Company

Common Stock Issued for Conversion of Convertible Notes and Debentures

During the nine months ended September 30, 2017 the following conversions occurred:

	●	$1,093,050 of convertible debentures and $162,739 of accrued interest was converted at $5.20 per share into 241,500 shares of common stock;

	●	As partial settlement of a note payable to a relative of an Executive Officer, $100,000 was converted at $12.00 per share into 8,334 shares of common stock;

	●	As partial settlement of a related party note, $55,000 of principal and $5,000 of interest was converted at $12.00 per share into 5,000 shares of common stock.

Common Stock Issued for Services

During the nine months ended September 30, 2017, the Company issued 6,250 shares of common stock with a total value of $53,500 to certain Board members and consultants for services rendered.

	For the Three Months Ended					For the Nine Months Ended
	September 30,					September 30,
	2018			2017		2018		2017

Research and development expense	$	99,129		$	-	$	579,754	$	-
Selling, general and administrative expense		(67,139	)		261,153		441,871		385,013

Total share-based compensation	$	31,990		$	261,153	$	1,021,625	$	385,013

XML 20 R11.htm IDEA: XBRL DOCUMENT

Common Stock Options

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Stock Options

Note 6 – Common Stock Options

Equity Incentive Plan

Board and Key Employee Option Grants

The fair value was computed using the Black Scholes method using the following weighted-average assumptions:

Expected life	5.06 Years
Exercise price	$	8.00
Expected volatility		125	%
Expected dividends		None
Risk-free interest rate		2.81	%

CEO Stock Option Incentive

	●	112,500 options if FDA marketing authorization is obtained after January 1, 2018 and on or before July 1, 2018;

	●	75,000 options if FDA marketing authorization is obtained after July 1, 2018 and on or before January 1, 2019;

	●	37,500 options if FDA marketing authorization is obtained after January 1, 2019 and on or before January 1, 2020.

As of September 30, 2018, there are currently 178,293 options available for issuance under the Plan.

A summary of option activity for the nine months ended September 30, 2018 is presented below:

						Weighted		Aggregate
				Weighted		Average		Intrinsic
	Shares			Average		Remaining		Value of
	Under			Exercise		Contractual		Vested
	Options			Price		Life		Options
Outstanding at December 31, 2017		331,000		$	8.05		10.0 years	$	-
Issued		80,954		$	8.00
Adjustment		(37,500	)	$	8.00
Forfeited/Expired		(91,037	)	$	8.00
Outstanding at September 30, 2018		283,417		$	8.00		9.28 years	$	-
Vested at September 30, 2018		195,198		$	8.00		9.22 years	$	-

XML 21 R12.htm IDEA: XBRL DOCUMENT

Common Stock Warrants

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Stock Warrants

Note 7 – Common Stock Warrants

A summary of warrant activity for the nine months ended September 30, 2018 is presented below:

						Weighted		Aggregate
				Weighted		Average		Intrinsic
	Shares			Average		Remaining		Value of
	Under			Exercise		Contractual		Vested
	Warrants			Price		Life		Warrants
Outstanding at December 31, 2017		1,184,998		$	9.16		1.9 years	$	1,160,404
Issued		47,186		$	7.29
Exercised		-
Expired/Forfeited		(625	)	$	0.01
Outstanding at September 30, 2018		1,231,559		$	9.02		1.1 years	$	1,155,860

The Company recognized $35,446 and $70,360 as share-based compensation related to the vesting of warrant shares for the three and nine months ended September 30, 2017, respectively.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Organization

Organization

Principles of Consolidation

Principles of Consolidation

Basis of Presentation

Basis of Presentation

Going Concern

Going Concern

Basic and Diluted Loss Per Share

Basic and Diluted Loss Per Share

	For the Three and Nine Months Ended
	September 30,
	2018		2017
Warrants to purchase shares		1,231,559		1,205,623
Stock options		283,417		127,500
Convertible notes		698,919		201,155

Convertible Debt

Convertible Debt

Adoption of New Accounting Policies

Adoption of New Accounting Policies

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 23 R14.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

As of September 30, 2018, and 2017, the following items were excluded from the computation of diluted net loss per common share as their effect is anti-dilutive:

	For the Three and Nine Months Ended
	September 30,
	2018		2017
Warrants to purchase shares		1,231,559		1,205,623
Stock options		283,417		127,500
Convertible notes		698,919		201,155

XML 24 R15.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following at September 30, 2018 and December 31, 2017:

	September 30, 2018		December 31, 2017

Raw materials	$	73,415	$	66,417
Work in progress		13,340		12,465
Finished goods		176,332		176,755

Total inventory		263,087		255,637
Less: carrying value of inventory not deemed to be a current asset		263,087		255,637

Inventory, included in current assets	$	-	$	-

XML 25 R16.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2018

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following at September 30, 2018 and December 31, 2017:

	September 30, 2018		December 31, 2017

Accrued interest	$	151,770	$	-
Accrued royalties		17,873		17,873
Accrued payroll and payroll taxes		58,868		7,529

Total Accrued Liabilities	$	228,511	$	25,402

XML 26 R17.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Schedule of Weighted Average Assumptions Using Black-Scholes Model

Expected life	2.5 years
Exercise price	$	7.29
Expected volatility		160	%
Expected dividends		n/a
Risk-free interest rate		2.35	%

Schedule of Notes Payable

Notes payable are summarized as follows:

	September 30, 2018		December 31, 2017
Convertible notes payable net of $786,821 in discount and loan costs; unsecured; interest at 8.00%; due March through May 2020	$	2,195,929	$	-

Convertible notes payable; unsecured; interest at 8.00%; due November 2020		1,206,931		1,206,931

Notes payable	$	3,402,860	$	1,206,931

XML 27 R18.htm IDEA: XBRL DOCUMENT

Common Stock (Tables)

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan

	For the Three Months Ended					For the Nine Months Ended
	September 30,					September 30,
	2018			2017		2018		2017

Research and development expense	$	99,129		$	-	$	579,754	$	-
Selling, general and administrative expense		(67,139	)		261,153		441,871		385,013

Total share-based compensation	$	31,990		$	261,153	$	1,021,625	$	385,013

XML 28 R19.htm IDEA: XBRL DOCUMENT

Common Stock Options (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Fair Value of Options Grants Using Black Scholes Method

The fair value was computed using the Black Scholes method using the following weighted-average assumptions:

Expected life	5.06 Years
Exercise price	$	8.00
Expected volatility		125	%
Expected dividends		None
Risk-free interest rate		2.81	%

Summary of Option Activity

A summary of option activity for the nine months ended September 30, 2018 is presented below:

						Weighted		Aggregate
				Weighted		Average		Intrinsic
	Shares			Average		Remaining		Value of
	Under			Exercise		Contractual		Vested
	Options			Price		Life		Options
Outstanding at December 31, 2017		331,000		$	8.05		10.0 years	$	-
Issued		80,954		$	8.00
Adjustment		(37,500	)	$	8.00
Forfeited/Expired		(91,037	)	$	8.00
Outstanding at September 30, 2018		283,417		$	8.00		9.28 years	$	-
Vested at September 30, 2018		195,198		$	8.00		9.22 years	$	-

XML 29 R20.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Warrant Activity

A summary of warrant activity for the nine months ended September 30, 2018 is presented below:

						Weighted		Aggregate
				Weighted		Average		Intrinsic
	Shares			Average		Remaining		Value of
	Under			Exercise		Contractual		Vested
	Warrants			Price		Life		Warrants
Outstanding at December 31, 2017		1,184,998		$	9.16		1.9 years	$	1,160,404
Issued		47,186		$	7.29
Exercised		-
Expired/Forfeited		(625	)	$	0.01
Outstanding at September 30, 2018		1,231,559		$	9.02		1.1 years	$	1,155,860

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 30 R21.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Warrant to Purchase Shares [Member]
Antidilutive securities excluded from computation of earnings per share	1,231,559	1,205,623	1,231,559	1,205,623
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share	283,417	127,500	283,417	127,500
Convertible Notes [Member]
Antidilutive securities excluded from computation of earnings per share	698,919	201,155	698,919	201,155

XML 31 R22.htm IDEA: XBRL DOCUMENT

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 73,415	$ 66,417
Work in progress	13,340	12,465
Finished goods	176,332	176,755
Total inventory	263,087	255,637
Less: carrying value of inventory not deemed to be a current asset	263,087	255,637
Inventory, included in current assets

XML 32 R23.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued interest	$ 151,770
Accrued royalties	17,873	17,873
Accrued payroll and payroll taxes	58,868	7,529
Total accrued liabilities	$ 228,511	$ 25,402

XML 33 R24.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
Notes Payable (Details Narrative) - USD ($)	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Debt instrument interest rate	10.00%	10.00%
Debt conversion price per share	$ 0.98	$ 0.98
Warrants to purchase conversion shares, percentage	10.00%	10.00%
Debt discount		$ 1,061,579
Interest expenses, related to amortization of discount	$ 133,977	274,758
Unamortized balance of discount	786,821	786,821
Repayment of debentures			$ 285,389
Individual Related to Executive Officer [Member]
Convertible promissory notes, shares conversion			8,334
Number of warrant issued shares of common stock			8,334
Exercise price of warrants			$ 12.00
Debt principal amount			$ 89,389
Interest expenses, related to amortization of discount			39,071
Proceeds from convertible debt			$ 100,000
Convertible Debentures [Member]
Debt conversion price per share			$ 5.20
Accrued interest payable			$ 162,739
Convertible promissory notes, shares conversion			241,500
Repayment of principal			$ 164,000
Repayment of accrued interest			25,700
Debt instrument interest amount			25,700
Debt conversion of convertible debt			1,093,050
Debt conversion interest amount			$ 162,739
Placement Agent [Member] \| Warrants [Member]
Beneficial conversion feature, value		463,983
Non-accountable expenses		25,000
Cash commission fees	$ 322,275	$ 322,275
Number of warrant issued shares of common stock	47,186	47,186
Value of warrants issued	$ 275,321	$ 275,321
Exercise price of warrants	$ 5.83	$ 5.83
Convertible Notes [Member]
Debt instrument interest rate	8.00%	8.00%
Debt conversion price per share	$ 6.30	$ 6.30
Public offering price, percentage	90.00%	90.00%
Convertible promissory notes, value		$ 2,982,750
Accrued interest payable	$ 127,631	127,631
Beneficial conversion feature, value		463,983
Debt principal amount	$ 597,596	$ 597,596
Convertible Notes [Member] \| Maximum [Member]
Fair value of common stock price, per share	$ 7.28	$ 7.28
Convertible Notes [Member] \| Minimum [Member]
Debt conversion price per share	$ 6.30	$ 6.30
Common Stock [Member]
Convertible promissory notes, shares conversion		493,740
Principal [Member]
Convertible promissory notes, shares conversion		473,467
Interest [Member]
Convertible promissory notes, shares conversion		20,273
Related-Party Notes Payable [Member]
Convertible promissory notes, shares conversion			5,000
Number of warrant issued shares of common stock			5,000
Exercise price of warrants			$ 12.00
Debt principal amount			$ 105,000
Debt instrument interest amount			5,000
Debt conversion of convertible debt			60,000
Repayment of debentures			50,000
Shor term advances			35,000
Third-Party Note [Member]
Debt principal amount			32,000
Interest expenses, related to amortization of discount			$ 1,185

XML 34 R25.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Weighted Average Assumptions Using Black-Scholes Model (Details)	9 Months Ended
	Sep. 30, 2018 $ / shares
Expected Life [Member]
Fair value assumption, term	2 years 6 months
Exercise Price [Member]
Fair value assumption, exercise price	$ 7.29
Expected Volatility [Member]
Fair value assumption, percent	160.00%
Expected Dividend [Member]
Fair value assumption, percent	0.00%
Risk Free Interest Rate [Member]
Fair value assumption, percent	2.35%

XML 35 R26.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Notes payable	$ 3,402,860	$ 1,206,931
Convertible Notes Payable [Member]
Notes payable	2,195,929
Convertible Notes Payable 1 [Member]
Notes payable	$ 1,206,931	$ 1,206,931

XML 36 R27.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Debt interest percentage	10.00%
Convertible Notes Payable [Member]
Convertible notes payable	$ 786,821	$ 786,821
Debt interest percentage	8.00%	8.00%
Debt instrument term description	Due March through May 2020	Due March through May 2020
Convertible Notes Payable 1 [Member]
Debt interest percentage	8.00%	8.00%
Debt instrument term description	Due November 2020	Due November 2020

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 37 R28.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
Common Stock (Details Narrative) - USD ($)	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Cash offering costs			$ 664,452
Commission fees to the placement agents			$ 826,146
Commission fees to the placement agents, shares			67,326
Subscriptions received			$ 6,531,567
Adjusted maximum offering amount			$ 8,200,000	$ 303,401
Debt conversion price per share	$ 0.98	$ 0.98
Number of common stock shares issued for services	75,000
Number of common stock shares issued for services, value	$ 472,000
Common Stock [Member]
Number of common stock shares issued for services			6,250
Number of common stock shares issued for services, value			$ 53,500
Convertible Debentures [Member]
Debt conversion of convertible debt			1,093,050
Accrued interest			$ 162,739
Debt conversion price per share			$ 5.20
Debt conversion of convertible shares issued			241,500
Convertible Debentures [Member] \| Related Party [Member]
Debt conversion of convertible debt			$ 55,000
Accrued interest			$ 5,000
Debt conversion price per share			$ 12.00
Debt conversion of convertible shares issued			5,000
Convertible Debentures [Member] \| Executive Officer [Member]
Debt conversion of convertible debt			$ 100,000
Debt conversion price per share			$ 12.00
Debt conversion of convertible shares issued			8,334
Through February 2018 [Member]
Cash offering costs		$ 303,401

XML 38 R29.htm IDEA: XBRL DOCUMENT

Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total share-based compensation	$ 31,990	$ 261,153	$ 1,021,625	$ 385,013
Research and Development Expense [Member]
Total share-based compensation	99,129		579,754
Selling, General and Administrative Expenses [Member]
Total share-based compensation	$ (67,139)	$ 261,153	$ 441,871	$ 385,013

XML 39 R30.htm IDEA: XBRL DOCUMENT

Common Stock Options (Details Narrative) - USD ($)		1 Months Ended			3 Months Ended	9 Months Ended
Common Stock Options (Details Narrative) - USD ($)	Aug. 09, 2017	May 31, 2018	Mar. 31, 2018	Jul. 31, 2017	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Common stock shares authorized					120,000,000	120,000,000	120,000,000
Common stock shares issued					3,861,848	3,861,848	3,861,848
Number of option granted	75,000					80,954
Option exercise price per share						$ 8.00
Number of shares issued for service					75,000
Number of shares issued for service, value					$ 472,000
Number of shares issued for service, reduction					37,500
Number of shares issued for service, reduction value					$ 223,000
Stock option term description					The service period was extended from December 31, 2018 to December 31, 2019.
Net reversal of compensation expense					$ 195,272	$ 27,429
U.S. Food and Drug Administration [Member]
Stock option expire year						10 years
Board and Key Employee Option Grants [Member]
Number of option forfeited due to employee's separation and directors resignation						48,893
Amount of future expense eliminated						$ 140,303
Stock option expenses					227,262	$ 1,049,054
Directors [Member]
Number of option granted			938
Option exercise price per share			$ 8
Vested price per share			$ 6.18
Fair value of vested			$ 5,794
Chief Medical Officer [Member]
Number of option granted		30,000
Option exercise price per share		$ 8
Vested price per share		$ 6.28
Fair value of vested		$ 188,289
Board Members [Member]
Number of option granted		50,016
Vested price per share						$ 6.07
Fair value of vested						$ 303,696
Fees in lieu of cash		$ 105,500
Through September 2019 [Member]
Unrecognized expense					$ 162,488	$ 162,488
Stock option expire year						1 year
On or Before July 1, 2018 [Member] \| U.S. Food and Drug Administration [Member]
Number of option granted						112,500
On or Before January 1, 2019 [Member] \| U.S. Food and Drug Administration [Member]
Number of option granted						75,000
On or Before January 1, 2020 [Member] \| U.S. Food and Drug Administration [Member]
Number of option granted						37,500
From December 31, 2018 to December 31, 2019 [Member]
Amortization of compensation expense related to original estimate						$ 301,375
December 31, 2019 Estimate [Member]
Amortization of compensation expense related to original estimate						106,103
Through December 31, 2019 [Member]
Amortization of compensation expense related to original estimate						$ 116,281
Stock Incentive Plan [Member]
Common stock shares authorized				500,000
Common stock shares issued				40,000
Common stock shares issued percentage				8.00%
Stock Incentive Plan [Member] \| January 1, 2027 [Member]
Common stock shares authorized				900,000
Stock Option Incentive Plan [Member]
Number of options available for issuance					178,293	178,293

XML 40 R31.htm IDEA: XBRL DOCUMENT

Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) - Board and Key Employee Option Grants [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares
Expected life	5 years 22 days
Exercise price	$ 8.00
Expected volatility	125.00%
Expected dividends	0.00%
Risk-free interest rate	2.81%

XML 41 R32.htm IDEA: XBRL DOCUMENT

Common Stock Options - Summary of Option Activity (Details) - USD ($)		9 Months Ended
	Aug. 09, 2017	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares Under Option, Outstanding Beginning Balance		331,000
Shares Under Option, Issued	75,000	80,954
Shares Under Option, Adjustment		(37,500)
Shares Under Option, Forfeited/Expired		(91,037)
Shares Under Option, Outstanding Ending Balance		283,417
Shares Under Option, Vested		195,198
Weighted Average Exercise Price, Outstanding Beginning Balance		$ 8.05
Weighted Average Exercise Price, Issued		8.00
Weighted Average Exercise Price, Adjustment		8.00
Weighted Average Exercise Price, Forfeited/Expired		8.00
Weighted Average Exercise Price, Outstanding Ending Balance		8.00
Weighted Average Exercise Price, Vested		$ 8.00
Weighted Average Remaining Contractual Life, Outstanding Beginning		10 years
Weighted Average Remaining Contractual Life, Outstanding Ending		9 years 3 months 11 days
Weighted Average Remaining Contractual Life, Vested		9 years 2 months 19 days
Aggregate Intrinsic Value Vested Options, Outstanding Beginning Balance
Aggregate Intrinsic Value Vested Options, Outstanding Ending Balance
Aggregate Intrinsic Value Vested Options, Vested

XML 42 R33.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Common Stock Warrants (Details Narrative) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation	$ 31,990	$ 261,153	$ 1,021,625	$ 385,013
Warrants [Member]
Intrinsic value	$ 7.28		$ 7.28
Stock-based compensation		$ 35,446		$ 70,360

XML 43 R34.htm IDEA: XBRL DOCUMENT

Common Stock Warrants - Schedule of Warrant Activity (Details) - Warrants [Member]	9 Months Ended
	Sep. 30, 2018 USD ($) $ / shares shares
Shares Under Warrants Outstanding, Beginning Balance \| shares	1,184,998
Shares Under Warrants, Issued \| shares	47,186
Shares Under Warrants, Exercised \| shares
Shares Under Warrants, Expired/Forfeited \| shares	(625)
Shares Under Warrants Outstanding, Ending Balance \| shares	1,231,559
Weighted-Average Exercise Price, Outstanding Beginning Balance \| $ / shares	$ 9.16
Weighted-Average Exercise Price, Issued \| $ / shares	7.29
Weighted-Average Exercise Price, Exercised \| $ / shares
Weighted-Average Exercise Price, Expired/Forfeited \| $ / shares	0.01
Weighted-Average Exercise Price, Outstanding Ending Balance \| $ / shares	$ 9.02
Weighted-Average Remaining Contractual Life, Outstanding Beginning Balance	1 year 10 months 25 days
Weighted-Average Remaining Contractual Life, Outstanding Ending Balance	1 year 1 month 6 days
Aggregate Intrinsic Value of Vested Warrants Outstanding Beginning \| $	$ 1,160,404
Aggregate Intrinsic Value of Vested Warrants Outstanding Ending \| $	$ 1,155,860

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 92 199 1 false 44 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://prolunginc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://prolunginc.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://prolunginc.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://prolunginc.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://prolunginc.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 6 false false R7.htm 00000007 - Disclosure - Inventory Sheet http://prolunginc.com/role/Inventory Inventory Notes 7 false false R8.htm 00000008 - Disclosure - Accrued Liabilities Sheet http://prolunginc.com/role/AccruedLiabilities Accrued Liabilities Notes 8 false false R9.htm 00000009 - Disclosure - Notes Payable Notes http://prolunginc.com/role/NotesPayable Notes Payable Notes 9 false false R10.htm 00000010 - Disclosure - Common Stock Sheet http://prolunginc.com/role/CommonStock Common Stock Notes 10 false false R11.htm 00000011 - Disclosure - Common Stock Options Sheet http://prolunginc.com/role/CommonStockOptions Common Stock Options Notes 11 false false R12.htm 00000012 - Disclosure - Common Stock Warrants Sheet http://prolunginc.com/role/CommonStockWarrants Common Stock Warrants Notes 12 false false R13.htm 00000013 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - Inventory (Tables) Sheet http://prolunginc.com/role/InventoryTables Inventory (Tables) Tables http://prolunginc.com/role/Inventory 15 false false R16.htm 00000016 - Disclosure - Accrued Liabilities (Tables) Sheet http://prolunginc.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://prolunginc.com/role/AccruedLiabilities 16 false false R17.htm 00000017 - Disclosure - Notes Payable (Tables) Notes http://prolunginc.com/role/NotesPayableTables Notes Payable (Tables) Tables http://prolunginc.com/role/NotesPayable 17 false false R18.htm 00000018 - Disclosure - Common Stock (Tables) Sheet http://prolunginc.com/role/CommonStockTables Common Stock (Tables) Tables http://prolunginc.com/role/CommonStock 18 false false R19.htm 00000019 - Disclosure - Common Stock Options (Tables) Sheet http://prolunginc.com/role/CommonStockOptionsTables Common Stock Options (Tables) Tables http://prolunginc.com/role/CommonStockOptions 19 false false R20.htm 00000020 - Disclosure - Common Stock Warrants (Tables) Sheet http://prolunginc.com/role/CommonStockWarrantsTables Common Stock Warrants (Tables) Tables http://prolunginc.com/role/CommonStockWarrants 20 false false R21.htm 00000021 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://prolunginc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Organization and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 21 false false R22.htm 00000022 - Disclosure - Inventory - Schedule of Inventory (Details) Sheet http://prolunginc.com/role/Inventory-ScheduleOfInventoryDetails Inventory - Schedule of Inventory (Details) Details 22 false false R23.htm 00000023 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://prolunginc.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 23 false false R24.htm 00000024 - Disclosure - Notes Payable (Details Narrative) Notes http://prolunginc.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://prolunginc.com/role/NotesPayableTables 24 false false R25.htm 00000025 - Disclosure - Notes Payable - Schedule of Weighted Average Assumptions Using Black-Scholes Model (Details) Notes http://prolunginc.com/role/NotesPayable-ScheduleOfWeightedAverageAssumptionsUsingBlack-scholesModelDetails Notes Payable - Schedule of Weighted Average Assumptions Using Black-Scholes Model (Details) Details 25 false false R26.htm 00000026 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://prolunginc.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 26 false false R27.htm 00000027 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://prolunginc.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 27 false false R28.htm 00000028 - Disclosure - Common Stock (Details Narrative) Sheet http://prolunginc.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://prolunginc.com/role/CommonStockTables 28 false false R29.htm 00000029 - Disclosure - Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan (Details) Sheet http://prolunginc.com/role/CommonStock-ScheduleOfCompensationCostForShare-basedPaymentArrangementsAllocationOfShare-basedCompensationCostsByPlanDetails Common Stock - Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan (Details) Details 29 false false R30.htm 00000030 - Disclosure - Common Stock Options (Details Narrative) Sheet http://prolunginc.com/role/CommonStockOptionsDetailsNarrative Common Stock Options (Details Narrative) Details http://prolunginc.com/role/CommonStockOptionsTables 30 false false R31.htm 00000031 - Disclosure - Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) Sheet http://prolunginc.com/role/CommonStockOptions-ScheduleOfFairValueOfOptionsGrantsUsingBlackScholesMethodDetails Common Stock Options - Schedule of Fair Value of Options Grants Using Black Scholes Method (Details) Details 31 false false R32.htm 00000032 - Disclosure - Common Stock Options - Summary of Option Activity (Details) Sheet http://prolunginc.com/role/CommonStockOptions-SummaryOfOptionActivityDetails Common Stock Options - Summary of Option Activity (Details) Details 32 false false R33.htm 00000033 - Disclosure - Common Stock Warrants (Details Narrative) Sheet http://prolunginc.com/role/CommonStockWarrantsDetailsNarrative Common Stock Warrants (Details Narrative) Details http://prolunginc.com/role/CommonStockWarrantsTables 33 false false R34.htm 00000034 - Disclosure - Common Stock Warrants - Schedule of Warrant Activity (Details) Sheet http://prolunginc.com/role/CommonStockWarrants-ScheduleOfWarrantActivityDetails Common Stock Warrants - Schedule of Warrant Activity (Details) Details 34 false false All Reports Book All Reports lung-20180930.xml lung-20180930.xsd lung-20180930_cal.xml lung-20180930_def.xml lung-20180930_lab.xml lung-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 50 0001493152-18-016106-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-016106-xbrl.zip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